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Abstract
Infectious diseases frequently cause significant impacts on global health and economies.
For instance, bacterial meningitis is one of such diseases worldwide. Because infectious diseases
often occur in high-poverty regions and are the leading cause of death in developing countries, a
simple and low-cost method is in great need for immediate and early diagnosis of infectious
diseases. Recently, microfluidic lab-on-a-chip offers a unique opportunity for various biomedical
applications due to a variety of advantages such as low cost, low reagent consumption, integration,
miniaturization, portability, and automation. Since different chip substrates have different
advantages and limitations, hybrid devices can draw more benefits from different substrates.
Therefore, we developed multiple paper/polymer hybrid microfluidic biochips integrated with
loop-mediated isothermal amplification (LAMP) for high-sensitivity infectious disease diagnosis
at low cost.
We for the first time developed a low-cost paper/polydimethylsiloxane (PDMS) hybrid
microfluidic biochip for rapid, sensitive and instrument-free detection of a main meningitiscausing bacterium, N. meningitidis. The hybrid microfluidic biochip with paper inside enabled
stable testing results over a much longer period of time than a paper-free microfluidic biochip. The
results could be observed by the naked eye under a portable UV light pen, without using any
specialized laboratory instruments. Although no any specialized instruments were used, the limit
of detection (LOD) of 3 copies of the template DNA per LAMP zone for N. meningitidis was
readily achieved. Moreover, the direct detection of pathogenic microorganisms was successfully
achieved, without laborious sample preparation process or the use of centrifuges.
In addition, we demonstrated the broader application of our microfluidic approach by
testing the whooping cough-causing bacterium, B. pertussis. The bacterial cell lysis protocol was
further optimized by using artificial clinical samples. The LOD was estimated to be 5 DNA copies
of the target B. pertussis per LAMP zone. This hybrid microfluidic biochip and method were
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further validated by testing 100 human clinical samples, and high sensitivity and specificity
comparable to costly qPCR were demonstrated.
On the basis of the aforementioned singleplexed pathogen detection (either N. meningitidis
or B. pertussis), by performing multiple singleplexed LAMP reactions in multiple different
compartments in parallel, we developed another low-cost paper/PDMS hybrid microfluidic
biochip for multiplexed detection of three pathogens, N. meningitidis, S. pneumoniae and Hib,
which cause most of the bacterial meningitis. It was found that the LODs were a few DNA copies
per LAMP zone for each pathogen target.
At last, to address difficulties of conventional multiplex LAMP (mLAMP) in identification
and quantitation of multiple targets, we developed a new paper/poly(methyl methacrylate)
(PMMA) hybrid CD-like microfluidic SpinChip integrated with mLAMP reactions and ssDNA
probe-functionalized graphene oxide (GO) nanosensors for simple quantitative detection of
infectious diseases. Multiple DNA targets were isothermally amplified in a single microzone (i.e.
mLAMP). Amplified DNA targets were further identified and quantified by integrated capture
probe-functionalized GO nanosensors in different detection microwells afterward. Paper placed
inside the detection microwells facilitated the integration of GO nanosensors, thus avoiding
complicated surface modifications. No washing or amplicon purification steps were needed during
the whole assay process. This work provides a simple, integrated and effective microfluidic
approach for quantitative mLAMP detection.
These low-cost paper/polymer hybrid microfluidic biochips have great potential for pointof-care (POC) disease diagnosis, especially in low-resource settings such as physician’s office and
developing nations.
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Chapter 1: Introduction
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1.1

Infectious diseases
Infectious diseases, caused by pathogenic microorganisms (bacteria, viruses, fungi or

parasites), can directly or indirectly transmit from one person to another. Although great progress
has been made to prevent infectious diseases, multiple infectious diseases such as malaria,
tuberculosis, AIDS, hepatitis, Zika, Ebola, meningitis, and pertussis still cause thousands of deaths
every year. The emergence of 335 infectious diseases that have been reported between 1940 and
2004 in the global human population has generated an extremely significant impact on global
health and economies.1-2
1.1.1 Meningitis
Among various global infectious diseases, meningitis, a severe infection affecting the
protective membranes covering the brain and spinal cord known as the meninges, can become fatal
in as early as 24 hours after symptoms occur.3 The main symptoms of meningitis include a severe
headache, fever, and neck stiffness. Meningitis is one of the most dangerous diseases due to its
high morbidity and mortality, which can be caused by infection with bacteria, viruses, fungi and
parasites.
Bacterial meningitis remains the most serious form of this disease. As reported by World
Health Organization (WHO), without epidemics one million cases of bacterial meningitis are
estimated to occur and around 200,000 die annually worldwide.4 Bacterial meningitis is a serious
issue especially in developing countries or high poverty regions, where higher case-fatality rates
(37-60%) have been reported.4 In the ‘Meningitis Belt’ of Africa, bacterial meningitis remains a
major unresolved public health problem, where recurrent unpredictable epidemics often occur.5
Neisseria meningitidis (N. meningitidis), Streptococcus pneumoniae (S. pneumoniae), and
Haemophilus influenzae type b (Hib) are three major pathogens causing bacterial meningitis.4 In
addition, tuberculous meningitis, caused by Mycobacterium tuberculosis, is also a serious public
health problem worldwide with high mortality especially for Human immunodeficiency virus
(HIV) infected patients with immune problems.6 As a medical emergency, the immediate antibiotic

2

therapy is imperative for bacterial meningitis, which must not be postponed by diagnostic delays.7
In addition, identification of the exact bacteria causing the disease is vital because treatment and
antibiotics differ for each type.
Viral meningitis is commonly caused by Enteroviruses, herpes simplex virus (HSV-2,
HSV-1), and varicella zoster virus. The incidence of viral meningitis is often in young children
and decreases with age.8 The most common fungal meningitis is cryptococcal meningitis, which
is caused by Cryptococcus neoformans. The cryptococcal meningitis is a serious disease for
infected adults in Sub-Saharan Africa.9 Fungal meningitis can also be caused by other fungi such
as Blastomyces dermatitidis, Histoplasma capsulatum, Coccidioides immitis and Candida species.
Eosinophilic meningitis is the most common parasitic meningitis, primarily caused by
Angiostrongylus cantonensis, which is a major public health concern in Brazil and some Asian
countries such as Thailand.10 Other parasites such as Gnathostoma spinigerum and Schistosoma
can also cause parasitic meningitis.
1.1.2 Pertussis
Pertussis, also known as whooping cough, is a highly contagious disease that is caused by
the bacterium Bordetella pertussis (B. pertussis). Despite the high vaccination coverage in many
countries for more than 50 years, vaccine-preventable pertussis remains endemic worldwide.11-12
According to a report from the WHO, there were about 16 million pertussis cases worldwide in
2008 with 95% of these pertussis cases occurring in developing countries, leading to about 195,000
deaths from the disease.13 Pertussis is also a common disease in the United States with frequent
outbreaks. For example, in the most recent peak year of 2012, 48,277 cases of pertussis were
reported, which was the highest level since 1956.14
Pertussis is commonly under-diagnosed due to the mild or subclinical infections in most
cases. The symptoms of pertussis present with a runny nose, mild cough, nasal congestion, and
low-grade fever. Other Bordetella species such as Bordetella parapertussis (B. parapertussis),
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Bordetella holmesii (B. holmesii), and other respiratory infections may cause similar symptoms.15
The late-stage of pertussis might present the symptom of “whoop” like a cough.
1.1.3 Current technologies for infectious disease diagnosis
Due to the high fatality (e.g. bacterial meningitis) and the high number of infections (e.g.
pertussis) caused by untreated infectious diseases, and considering their high mortality in rural
high-poverty areas, a simple, low-cost, rapid and highly sensitive approach for immediate
infectious disease diagnosis is in great need. WHO has provided the guidelines for a successful
diagnostic technology in the developing world as ASSURED which means affordable, sensitive,
specific, user-friendly, robust and rapid, equipment free, and deliverable.16
The current commonly used diagnostic methods for infectious diseases such as bacterial
meningitis and pertussis include bacterial culture, gram staining, enzyme-linked immunosorbent
assay (ELISA), and nucleic acid amplification-based methods such as quantitative real-time
polymerase chain reaction (qPCR) and loop-mediated isothermal amplification (LAMP).
However, those common infectious disease diagnostic methods have their own limitations and are
not able to satisfy the guidelines and requirements provided by WHO. Multiple variables including
lack of effective test system and personnel expertise, delay in specimen collection and
transportation to the laboratory, and costly instrumentation may affect laboratory diagnosis of
infectious diseases.17
Microbiological culture
Microbiological culture is a well-established significant tool of growing microbial
organisms by using predetermined media in a laboratory setting under appropriate conditions.18
Microbiological culture is commonly used as a significant approach to identify a variety of
infectious diseases including bacterial meningitis and pertussis based on the specific characteristics
of the culturing microbial organisms. However, the limitations of microbiological culture are
obvious. Microbiological culture needs a long time to achieve the identification results, usually up
to days or even weeks for the identification.19-20 In addition, the detection sensitivity of
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microbiological culture is low, especially for patients who have received antibiotic pre-treatment.21
For example, the sensitivities of a microbiological culture assay for S. pneumoniae infected
patients with and without antibody treatment were found as low as 46.3% (19 out of 41 patients)
and 21.4% (9 out of 422 patients), respectively.22 According to a study, the sensitivity of a
microbiological culture assay for pertussis diagnosis was only 58% (288 out of 496 patients).23
Gram stain
Gram stain is a staining method used to differentiate bacterial species. Based on the
properties of the cell walls, the bacterial species can be differentiated into gram-positive and gramnegative groups. The gram-positive bacteria are stained violet from the primary stain, while the
gram-negative bacteria are stained pink from the counterstain after washing.24
As an empirical diagnostic tool, gram stain is used to identify the bacterial species based
on their specific morphological characteristics. For example, N. meningitidis bacteria appear as
gram-negative coffee-bean shaped diplococci, S. pneumoniae bacteria appear as gram-positive
lanceolate diplococci or short chains, Haemophilus influenzae (H. influenzae) bacteria appear as
gram-negative small rod or randomly arranging coccobacilli, and B. pertussis bacteria appear as
gram-negative coccobacilli independently or in pairs.4, 25
Gram stain is mainly used as a preliminary identification of bacterial species that cause the
infectious diseases. Usually, gram stain cannot be solely used and should be employed by
combining the other diagnostic tools such as traditional microbiological culture and molecular
techniques. Although gram stain may aid in providing a fast identification in laboratory settings,
its sensitivity is low. Gram stain even has a lower detection rate for patients previously treated
with antimicrobial therapy. In addition, well-trained personnel is required to perform gram stain
due to the fact that sometimes poor staining occurs.26
Enzyme-linked immunosorbent assay (ELISA)
ELISA, a diagnostic tool for detecting and measuring biomarkers based on the binding of
antibodies and antigens, has been widely used in infectious disease diagnosis.27 ELISA can detect
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the etiologic agents of diseases directly from clinical samples, which is very useful for rapid
detection of uncultivable or fastidious microorganisms.
Meningitis diagnosis by using ELISA is mainly focused on tuberculous meningitis. For
example, several publications reported the early-secreted antigenic target 6 (ESAT-6)-based
ELISA for tuberculous meningitis diagnosis, with sensitivities and specificities of 80-90% and 9294%, respectively.28-30 In addition, the ELISA assay by employing monoclonal antibody for the
antigen 85 complex was also reported for tuberculous meningitis diagnosis, with sensitivity of
84% and specificity of 91%.31 ELISA has also been reported for diagnosis of cryptococcal
meningitis by detecting the glucuronoxylomannan with a high sensitivity of 98.4% (the specificity
data is not shown).32 Tomanakan et al. reported an ELISA assay by employing circulating antibody
of Angiostrongylus cantonensis for diagnosis of eosinophilic meningitis.33 The sensitivity was
found to be 81.3%, and high specificity of this assay was demonstrated with cryptococcal
meningitis, bacterial meningitis, and the other parasitic infections. However, there are rare reports
on ELISA-based diagnosis for the major bacterial meningitis-causing pathogens such as N.
meningitidis, S. pneumoniae, and Hib.
ELISA using IgM and IgG antibodies targeting B. pertussis toxins and other serological
testing are also available for pertussis diagnosis but the sensitivity and specificity are low.34 The
IgA and IgG antibody response are also associated with other Bordetella species caused infections,
making the ELISA assay for pertussis not specific. Another challenge for ELISA-based pertussis
diagnosis is collecting the acute phase samples, whose antibody titers must be ≥2-fold higher than
those in the convalescent phase samples.17
ELISA is challenging to be used for accurate detection of certain pathogens such as B.
pertussis. In addition, ELISA usually requires complicated immobilization process, multiple
washing steps, and long-time incubation and blocking. Traditional ELISA assays also rely on
bulky instruments such as microplate readers.
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Quantitative real-time polymerase chain reaction (qPCR)
Based on a DNA polymerase (e.g. Thermus aquaticus, Taq) activity for primer-directed
target amplification, polymerase chain reaction (PCR) is the most widely adopted nucleic acid
amplification method with great applications in clinical, biological, and forensic analysis. PCR
typically consists of a series of 20-40 cycles, with each cycle usually consisting of 3 discrete steps.
First, in a denaturation step (94-96 °C), DNA melts, yielding single-stranded DNA (ssDNA)
molecules. Subsequently, in an annealing step (50-65°C), the polymerase attaches to a singlestrand and begins DNA formation. Finally, in an elongation or extension step (72 °C), DNA
polymerase synthesizes a new DNA strand which is complementary to the single-strand template.
qPCR is a molecular technique used to monitor and quantify the PCR amplification of the
target DNA by using either sequence-specific or non-sequence-specific fluorescent dyes. qPCR
has been employed for infectious disease diagnosis without the antibiotic pretreatment impact.22,
35-36

There are many reports on highly sensitive and specific qPCR-based singleplexed or

multiplexed bacterial meningitis diagnosis including N. meningitidis, S. pneumoniae, Hib, and so
on.35, 37 The whole qPCR assays could be completed within 1.5 hours.
qPCR-based pertussis diagnosis usually targets the IS481 sequence of B. pertussis, which
could achieve the LOD as low as a single organism per reaction.38 However, the IS481 sequence
also exists in B. holmesii genome, which makes the IS481–based qPCR for pertussis diagnosis not
specific.39
Usually, qPCR requires laborious and time-consuming sample preparation process such as
DNA purification, and specialized instruments in a well-equipment laboratory such as qPCR (e.g.,
QuantStudio™ 6 Flex Real-Time PCR System costs ~$60000), centrifuges, fluorescent
microscopes, and so on, which limits the broad application of qPCR, especially in low-resource
settings.
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Loop-mediated isothermal amplification (LAMP)
As a promising isothermal nucleic acid amplification method, LAMP has been developed
to amplify the target DNA at a constant temperature in a range of 60-65 °C. The high strand
displacement activity from a DNA polymerase (e.g. Bacillus stearothermophilus, Bst) and
identification of 6 distinct regions from 4 different primers in LAMP results in high specificity. 4041

LAMP has been reported with higher specificity and sensitivity, and less inhibiting effect to

clinical samples such as blood than qPCR.42-43 The principle of LAMP method can be seen in
Figure 1.1, including primer design, step of starting structure producing, and step of cycling
amplification.44
(a) Primer design. Six distinct regions, labeled F3, F2, F1, B1c, B2c and B3 from the 5’
end, are designated on the target DNA sequence. The F1c sequence is complementary to the F1
sequence. Inner primers (FIP and BIP) and outer primers (F3 and B3) are used in the LAMP
method. A hybrid primer FIP (BIP) consists of the F1c (B1c) sequence and the F2 (B2) sequence.
(b) The step of starting structure producing. DNA synthesis initiated from FIP proceeds.
The F2 region anneals to the F2c region on the target DNA sequence, initiating the elongation.
DNA amplification proceeds with BIP similarly. The F3 primer anneals to the F3c region, with
strand displacement DNA synthesis taking place. The single-strand DNA elongated from FIP is
replaced and released, forming a loop structure at its 5’ end (structure 4). With the single-strand
DNA as the template, and BIP and B3 primer to generate structure 5 in the same manner as
described earlier, DNA synthesis proceeds, possessing the loop structure at both ends (dumbbelllike structure).
(c) The step of cycling amplification. As the template of structure 5, self-primed DNA
synthesis initiates from the 3’ end F1 region, and the elongation starts from FIP annealing to the
single strand DNA of the F2c region in the loop structure. After several reaction steps, structure 7,
which is complementary to structure 5, is generated. And structure 5 is produced from structure 8
in a reaction similar to the process of structures 5-7. Intermediate structures (in the yellow boxes)
7a and 9a and structures 5a and 10a are produced from structures 6 and 8, respectively. Then
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structures 9a and 10a form structures 9 and 10, respectively, and the displaced strands 7a and 5a
form the dumbbell-like structures 7 and 5, respectively. More elongated structures 11 and 12 are
also produced.
LAMP is a promising isothermal nucleic acid amplification-based method for infectious
disease diagnosis. There have been several reports on rapid detection of pathogens such as
meningitis-causing bacteria including tuberculous meningitis, N. meningitidis, S. pneumoniae,
Hib, and B. pertussis by performing LAMP in tubes, which demonstrated comparable LODs and
much higher specificities comparing to PCR.45-50 However, none of these LAMP methods achieved
multiplexed bacterial meningitis detection.
Although there has been a growing attention for applications of the LAMP method in lowresource settings, it is challenging for the traditional tube-based LAMP method to achieve
multiplexed detection due to the complexities of multiple primer sets, and complicated ladderpattern amplicons as a mixture of stem-loop DNA products with various sizes.51-53 Those
conventional tube-based LAMP methods for simultaneous detection of multiple pathogens usually
can only identify the occurrence of amplifications, but cannot efficiently identify the specific target
pathogens.54-55 In addition, complicated sample preparation procedures such as DNA purification,
and bulky equipment such as thermal cyclers and centrifuges are usually needed, which limits the
application of LAMP as a point-of-care (POC) detection approach for infectious disease diagnosis
in low-resource settings.
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Figure 1.1: Principle of the LAMP method. (a) Primer design. (b) The step of starting structure
producing. (c) The step of cycling amplification. (Source: Adapted with permission
from Tomita et al., 2008. Copyright © 2008 Nature Publishing Group.44)
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1.2

Microfluidic lab-on-a-chip
Microfluidic lab-on-a-chip, also called “micro total analysis systems” (µTAS), is a

miniaturized device or system that can perform laboratory analysis functions by integrating one or
several functional units, with tiny amounts of fluids (microliters or below) manipulated and
controlled in genomic channels below hundreds of micrometers.56
The first miniaturized analysis device is a silicon-based gas chromatograph, which was
developed by Terry in the late 1970s.57 After that, the relevant research work of silicon-based
miniaturized analysis device mainly focused on the fabrication of components including
micropumps, microvalves, and chemical sensor (e.g. a pH-sensitive sensor).58 The application of
miniaturized analysis devices didn't become reemerged until 1990 when a silicon-based
miniaturized analyzer was reported to perform a high-pressure liquid chromatograph.59 In the same
year, Manz et al. presented the concept of “micro total analysis systems” (µTAS) that incorporated
with sample pretreatment, separation, and detection.60 Later on, the concept of microﬂuidic labon-a-chip was proposed. Since the 1990s, the µTAS or microfluidic lab-on-a-chip got a big boost
and has developed rapidly in the last few decades.61-62
1.2.1 Advantages and applications of microfluidic lab-on-a-chip
Microfluidic lab-on-a-chip has unique properties and significant advantages, typically:63-64
(1) Only minute amounts of samples and reagents are needed, usually in a level of
microliters or even down to picoliters. This is significant for bioanalysis since sometimes it is hard
to obtain large amounts of biological samples, such as clinical biopsy samples or trace forensic
samples from crime scenes. The low consumption of samples, reagents, and energy hence reduces
the cost as well.
(2) The microfluidic lab-on-a-chip is miniaturized, compact and portable, consuming much
less space.
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(3) As integration is the main concept of microfluidic lab-on-a-chip, several functional
units and techniques can be integrated on a single chip with great flexibility to perform various
laboratory functions.
(4) Fast and sensitive analysis can be achieved due to the properties such as short diffusion
distances, high surface-to-volume ratios, increased effective contact areas and concentrations,
etc.65
(5) High throughput can be achieved due to the massive parallelization and high-speed
serial processing.
(6) The microfluidic lab-on-a-chip has a better process control, defined concentration
gradients and controllable diffusion can be achieved.
Thanks to these unique properties and significant advantages, microfluidic lab-on-a-chip
has been widely used in various applications, including: (1) biological and chemical analysis, such
as medical diagnostics, single-cell analysis, protein analysis, nucleic acid analysis, environmental
monitoring, and food safety analysis; (2) synthesis of chemicals, nanomaterials, and
pharmaceutics; (3) drug discovery and controlled drug delivery; (4) 3D cell culture, organ-on-achip, and organism-on-a-chip.61, 65-75
The microfluidic lab-on-a-chip technology has great potential to improve global health
through the development of POC testing devices.76-77 POC testing is designed to move testing out
of well-equipped laboratories into other less hospitable sites. The capacity for on-site or in-field
POC testing is vital for immediate and convenient infectious disease diagnosis.
1.2.2 Substrates for microfluidic platform fabrication
Various substrates including silicon,78-79 glass,80-82 polymer (e.g. polydimethylsiloxane
(PDMS), poly(methyl methacrylate) (PMMA)),83-85 and paper86-88 have been used for microfluidic
platform fabrication. However, the different properties of these materials resulted in different
fabrication approaches and applications of their corresponding devices. For example, although
glass and silicon have good performance in chemical and thermal resistance, due to lack of rapid
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prototyping, expensive and complicated fabrications, stringent requirements on cleanroom facility,
and low biocompatibility, glass and silicon-based microfluidic platforms are not well suited to
POC applications. In addition, silicon is high-cost material and difficult for optical detection,
which further limits the fabrications and applications of silicon-based microfluidic devices in lowresource settings, such as developing nations.
Photolithography is the standard micromachining technique for glass and silicon-based
microfluidic devices.89-90 As a process for microfabrication of patterns on the surface of a substrate,
photolithography uses light (e.g. UV light) to pass through a geometric patterned photomask to a
photoresist material, a kind of light-sensitive chemicals, on the substrate, with a series of chemical
treatment procedures. For example, Figure 1.2 illustrates a typical photolithography process in
glass substrate microfabrication.91 The photolithography process for microfabrication of
glass/silicon substrate is expensive, complicated and time-consuming, and requires a cleanroom
environment and special facilities.
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Figure 1.2: A typical photolithography process of microfabrication for glass-based microfluidic
devices.
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As a low-cost material, the paper has an abundant cellulose fiber web with threedimensional (3D) microstructures and a high surface-to-volume ratio property. The biodegradable
cellulose paper can transport fluids via the capillary effect without the need of external pneumatic
pumps or electric power, making paper an ideal substrate for a disposable equipment-free testing
solution. The paper has been used for analytical and clinical chemistry since the early 20th century.
The low-cost, easy-to-use paper-based testing strips for testing pH, pregnancy, and diabetes have
been commercially available for decades. Since the Whitesides group introduced integrated paperbased microfluidic devices to offer low-cost and easy-to-use LOC platforms,92 paper has become
one of the most prevalent substrates for low-cost bioassays,93-95 such as immunochromatographic
strips (ICS) for quantitative or semi-quantitative assays.96 Without the stringent requirements of
cleanroom facilities, paper-based microfluidic devices can be easily fabricated by physical
blocking of pores in paper (e.g., photolithography, plotting), physical deposition of reagents on
paper surface (e.g., wax printing, inkjet etching, screen printing, flexography printing), chemical
modification of the paper surface (e.g., plasma treatment, inkjet printing), and other techniques
(e.g., laser printing, paper cutting and taping).66, 97-98
PDMS is the most broadly used silicon-based polymer substrate for microfluidic platform
fabrications. With attractive properties such as transparent, elastic, easy of curing and fabrications,
PDMS-based microfluidic devices have been widely used for various applications.99-101
Additionally, with unique gas permeability, PDMS is an ideal substrate for applications of
microfluidic 3D cell cultures and organ-on-a-chip.102-104 The common micromachining techniques
for PDMS-based microfluidic devices includes soft lithography, injection molding, imprinting,
casting, hot embossing, and laser ablation.61, 105 After the exposure in air plasma, PDMS film
bonding with themselves and many other materials (e.g. glass) can be easily achieved.
PMMA is a kind of thermoplastics that can be used as an economical alternative to glass.
PMMA is optically transparent, compatible with a variety of chemical and biological reagents,
easy of fabrication, and has moderately high mechanical stresses. These properties make PMMA
an attractive substrate for fabrication of various microfluidic devices with a variety of
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applications.106-108 Hot embossing and laser ablation are two common micromachining techniques
for PMMA-based microfluidic devices.85, 109 PMMA layer bonding can be easily achieved by
heating treatment or using adhesives.
1.2.3 Hybrid microfluidic platforms
Different materials have their own advantages and limitations. Despite its significant
advantages, the paper also has its own limitations. For instance, generally paper is not transparent,
though there are efforts to develop optically transparent paper.110-111 Paper substrates lack the high
performance in flow control demonstrated by polymer substrates. With attractive transparent
optical properties and high performance in flow manipulation, the cost-effective polymer
substrates like PDMS and PMMA have been widely used in microfluidic bio-applications.100, 104,
112-113

However, PDMS and PMMA are often associated with additional complicated chemical

surface modifications for probe immobilization.114-115
Therefore, the Li group has started the work on hybrid microfluidic platforms which can
draw benefits from multiple substrates. They developed the first paper/PDMS hybrid microfluidic
biochip integrated with aptamer-functionalized graphene oxide (GO) nanosensors for simple, onestep and multiplexed pathogen detection, as shown in Figure 1.3.116 The porous paper inside the
detection microwells provides a simple 3D substrate for nanosensor immobilization. The paper
substrate used in this hybrid biochip facilitates the physical adsorption of aptamer biosensors,
without any complicated surface treatment or aptamer probe immobilization in a PDMS or glassonly microfluidic system. Lactobacillus acidophilus was used as a bacterium model to develop the
microfluidic platform with the limit of detection (LOD) of 11.0 cfu/mL. This hybrid system has
also been successfully extended to the simultaneous detection of two infectious foodborne
pathogens (i.e., Staphylococcus aureus and Salmonella enterica) with high specificity. The onestep ‘turn-on’ pathogen assay in the hybrid microfluidic biochip only took ~10 minutes to
complete. Although the aforementioned method can directly measure microorganisms without
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complicated sample preparation due to the use of aptamers, the sensitivity might not be as high as
nucleic acid amplification-based methods.

Figure 1.3: A paper/PDMS hybrid microfluidic biochip integrated with aptamer-functionalized
GO nanosensors for multiplexed pathogen detection. (a) Chip layout; (b-c)
Detection principle. (d) Specificity test. (Source: Adapted with permission from
Zuo et al., 2013. Copyright © 2013 Royal Society of Chemistry.116)
1.3

Nucleic acid analysis on microfluidic devices
Nucleic acid biomarkers can be quantified or quantitated during the amplification step (e.g.

qPCR), or after the amplification step (e.g. through nucleic acid hybridization). Nucleic acid
analysis-based molecular biology techniques have been widely used in clinical diagnostics. These
nucleic acid analysis-based molecular biology techniques can detect the etiologic agents of
diseases directly from clinical samples, which is very useful for rapid detection of uncultivable or
fastidious microorganisms. Additionally, sensitive identification and characterization of pathogens
can be achieved by using amplified microbial nucleic acid.
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1.3.1 Nucleic acid amplification on microfluidic devices
Usually, a limited amount of DNA/RNA is available (e.g. only a single copy of specific
DNA in a cell), particularly when analyzing biological human samples. Therefore, amplification
of the target microbial DNA/RNA sequence is a key step in the nucleic acid analysis to enhance
the assay sensitivity for infectious disease diagnosis. There are several advantages to performing
nucleic acid amplification on microfluidic devices. The use of fully enclosed microfluidic devices
reduces the risk of sample contamination and implies low sample consumption, multiplex DNA
analysis, integration and portable devices realization with fewer manual steps.117-118
Microfluidic technologies have enabled miniaturization of nucleic acid amplification
process onto various microfluidic devices with a variety of benefits including high speed, low cost,
portability, high throughput, and automation. This microfluidic device-based nucleic acid
amplification has great applications such as infectious disease diagnosis, forensic analysis, medical
test, research, and so on.
PCR on microfluidic devices
Since the PCR process is highly temperature sensitive, thermal management has an
important role in microfluidic PCR operation to meet the required temperature set points at each
step of the process. There are two common strategies to facilitate thermal cycling of microfluidic
PCR, performing PCR process in a single zone with temperature modulated over time, or in three
independent heating zones where reaction mixture flow through with residence times matching the
corresponding PCR step.119 The good thermal management should be able to achieve a thermal
technique to rapidly increase the heating/cooling thermal cycling speed while maintaining a
uniform temperature distribution throughout the substrate containing the aqueous nucleic acid
sample. To meet these requirements, a variety of techniques are integrated with microfluidic
systems to regulate the temperature for thermal cyclings, such as Peltier components, Joule heating
(also known as resistive heating), microwaves, lasers, and wires.119-120
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By using either sequence-specific or non-sequence-specific fluorescent dyes, qPCR can
monitor and quantify the target nucleic acid during the PCR amplification process. Various
microfluidic devices based qPCR demonstrated their applications for pathogen detection and
human health diagnostics.
Strohmeier et al.121 developed a microfluidic centrifugal disk platform based parallel qPCR
for detection of up to 6 different foodborne pathogens, with spinning the cartridge on a low-cost
centrifugal test rig for the microfluidic routing of the liquids. The testing results showed that 50
pg and 500 pg Listeria monocytogenes genomic DNA samples were quantified to be 83 ± 17 pg
and 540 ± 116 pg respectively, and 50 pg and 500 pg Salmonella typhimurium DNA samples was
quantified to be 48 ± 4 pg and 643 ± 211 pg respectively. By using this microfluidic centrifugal
disk platform, they also performed a parallel allele-specific qPCR detection of seven point
mutations most relevant Kirsten rat sarcoma viral oncogene homolog (KRAS), which is considered
as an important predictive biomarker for response to cancer therapy targeting the epidermal growth
factor receptor.122 The testing results for genotyping 6 cancer cell lines agreed with dideoxysequencing with much reduced hands-on time (~2 hours of their approach versus up to ~20 hours
of dideoxy-sequencing). It also demonstrated that the DNA was genotyped correctly and
reproducibly, showing the potential of a valuable tool for routine diagnostics of KRAS mutations.
However, this microfluidic centrifugal disk platform-based qPCR relies on the support of a
commercially available thermocycler.
El-Sharoud et al. developed a fully integrated microfluidic platform for qPCR detection of
a foodborne pathogen Cronobacter sakazakii in a synthetic culture medium and in reconstituted
milk.123 This microfluidic device-based qPCR could detect Cronobacter sakazakii in tryptone soy
broth and reconstituted skim milk as low as 10 and 102 cfu/mL, respectively. However, the
operation of sample pretreatment is complicated, which involves cell separation by cationic
paramagnetic beads, chemical lysis of bacterial cells, and DNA purification with multiple washing
and elution steps. Oblath et al. presented a qPCR on a microfluidic device for the identification of
bacteria in saliva.124 The microfluidic device integrated a monolithic aluminum oxide membrane
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for DNA extraction and seven parallel reaction wells for qPCR. The LOD for Staphylococcus
aureus genomic DNA was achieved as low as 8-12 copies per assay. However, the fabrication of
the monolithic aluminum oxide membrane increases the complexity of the microfluidic device.
Additionally, the Peltier heating stage built for the thermal cycling is complicated.
So far, PCR is the most commonly used nucleic acid amplification method that is coupled
with the majority of miniaturized systems. However, PCR requires a carefully controlled sequence
of heating and cooling cycles. The microfabrication of heaters and temperature sensors on a chip
is complicated and expensive,68 making the microfluidic device-based qPCR not suitable for POC
testing.
LAMP on microfluidic devices
As an emerging isothermal DNA amplification technique, LAMP allows nucleic acid
amplification to be performed under thermally constant conditions, eliminating the complicated
and costly microfabrication of heating elements on a microfluidic chip.44 Despite the potential
applications of traditional off-chip LAMP for infectious disease diagnosis in low-resource settings,
bulky instruments such as thermal cyclers and centrifuges in laboratory settings are usually
required. In addition, it is challenging to achieve multiplexed detection by the traditional LAMP
that is performed in tubes. These limitations make the traditional LAMP not suitable for POC
diagnosis of infectious diseases.
Recently, taking the advantages of microfluidic lab-on-a-chip, various microfluidic devicebased LAMP has been developed for rapid singleplexed and multiplexed pathogen detection
including Staphylococcus aureus, Escherichia coli, and Mycobacterium tuberculosis.125-133 LAMP
on those microfluidic devices is demonstrated as a simple screening assay for POC diagnosis of
infectious diseases, coupled with different detection methods such as electrophoresis,134
colorimetric,126 absorbance,128-129 electrochemical127 and fluorescent135 detections.
1. Singleplexed LAMP detection with different detection methods
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The LAMP products is a mixture of stem-loop DNA products with various sizes.44
Therefore, the LAMP detection can be achieved based on the ladder-pattern bands of the LAMP
products. However, gel electrophoresis could potentially cause contamination for the sensitive
LAMP, 44 and is rarely coupled with LAMP on microfluidic devices.
Colorimetric detection is straightforward and does not require any bulky and expensive
instrumentation for detection. Safavieh et al. performed LAMP on a cassette-like device for
colorimetric detection of Staphylococcus aureus.126 However, the sensitivity of the colorimetric
detection is not high. The LOD was estimated about 200 cfu/mL.
Manganese loaded calcein is commonly used for fluorescence detection of LAMP. A large
number of pyrophosphate ions during LAMP reactions could effectively deprive the manganese
from the calcein and induce bright fluorescence. Zhang et al. developed an integrated
microcapillary-based LMAP for typing of the CYP2C19 gene from untreated blood samples.136
Inside the capillary, the FTA card for DNA extraction and all reagents were pre-loaded. Basically,
a trimmed piece of FTA membrane was inserted into the microcapillary. In accordance with the
diameter of the microcapillary, the DNA extraction card was prepared with an appropriate size
punched with a homemade sharp flat-tip needle. After insertion of the FTA card inside the
microcapillary with the aid of thinner tubing, purification reagent, amplification reagents, and
water droplets were pre-loaded into the microcapillary in sequence using negative-pressure
introduction. Then two customized PDMS plugs were used to protect the ends of the
microcapillary. In this way, each reagent/water droplet inside the microcapillary was quarantined
by adjacent air segments, preventing the movement of lipid droplets inside the microcapillary by
the surface tension at the interface under harsh conditions such as violent shaking. Without the
requirement for advanced instruments, this integrated microfluidic system can achieve on-site
pretreatment, extraction, amplification, and detection of nucleic acids within 150 min. Detection
results can be achieved based on the generated fluorescence of calcein under UV light. Although
on-chip sample preparation for DNA extraction can be achieved, the procedures are complicated
and require various reagents.
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LAMP can be detected by measuring the fluorescence signals produced via fluorescent
dyes that intercalate or directly label the DNA. Liu et al. developed a microfluidic device
integrated with LAMP for HIV detection.137-138 The nucleic acids could be captured by an FTA
membrane card in the chamber of the device, and used directly as templates for amplification
without elution. The fluorescence signals from the SYTO-9 Green DNA binding dye was
monitored by using a compact fluorescent reader. A LOD of fewer than 10 copies was
demonstrated. They further performed LAMP on a microfluidic device for rapid molecular
identification of Anopheles gambiae and Anopheles arabiensis by using mosquito tissues
directly.137 The FTA membrane card was used for isolation, concentration, and purification of
nucleic acids, and enabled the removal of inhibitors that reduce detection sensitivity. The
amplification products were finally detected with SYTO-9 Green DNA intercalating fluorescent
dye under a blue light-emitting diode to achieve a qualitative yes/no determination. Despite the
advantages of the FTA membrane card-based DNA extraction, the process is complicated and
requires multiple steps and various reagents. Ahmad et al. reported a charge-coupled device
(CCD)-based fluorescence imaging system for rapid detection of waterborne pathogens by
performing LAMP on a microfluidic device.135 By using a highly fluorescent DNA binding dye
(SYTO-82), this microfluidic LAMP assay allowed the analysis of low sample volume of 2 μL in
less than 20 min with the LOD of single DNA copy. However, the CCD-based fluorescence
imaging system is bulky, making the detection has to be performed only in a laboratory setting.
Absorbance of LAMP products is a way for microfluidic LAMP detection. Wang et al.
reported a magnetic bead-based assay for the rapid detection of Staphylococcus aureus by using
on-chip LAMP.128 A spectrophotometric analysis by measuring the absorbance values of the
optical density at a wavelength of 260 nm (OD260) for the LAMP amplicons has been utilized in
this study. Using this system with a spectrophotometer as the detector, the LOD of 10 fg/µL for
Staphylococcus aureus has been achieved. However, the support of a spectrophotometric detection
system is required.
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During LAMP reactions, an increasing quantity of the by-product of magnesium
pyrophosphate can result in turbidity due to precipitation. Therefore, LAMP can be determined via
photometry based on turbidity. Fang et al. performed LAMP on an eight-channel microfluidic
device for detection of Pseudorabies virus.129 The generated turbidity was measured by using an
optic sensor via absorbance. The LOD of the target nucleic acid sample was as low as 10 fg/μL.
However, the microfabrication of optical fibers on the microfluidic chip is complicated, and also
increases the cost.
Electrochemical assays for LAMP on microfluidic devices have also been developed to
identify and quantify bacteria. Safavieh et al. developed a microfluidic electrochemical system
integrated with LAMP for rapid detection of Escherichia coli.127 The system could detect 24
cfu/mL of Escherichia coli in 60 min implementing a linear sweep voltammetry method. However,
special and bulky instrument is required for electrochemical detection in a laboratory setting.
2. Multiplexed LAMP detection
To achieve multiplexed detection in traditional tube-based LAMP is a great challenge. By
taking advantage of microfluidics, multiple independent compartments can be easily fabricated in
a microfluidic device. Herein, multiplexed LAMP detection can be achieved by performing
parallel simplex LAMP reactions in each independent compartment of a microfluidic device.
Oh et al. presented a microfluidic centrifugal device for colorimetric detection of multiple
foodborne pathogen by LAMP.139 Genetic analysis of 25 pathogen samples was performed in the
microfluidic centrifugal system with five identical structures in a high-throughput manner.
Eriochrome Black T, a well-known metal indicator causing color change of the solution according
to the Mg2+concentration, was used for the colorimetric detection of the LAMP products. With the
decrease in concentration of Mg2+ during the LAMP reaction for the target gene, the color of the
reagent mixture with EBT changes from initial purple to sky blue. By using pathogenic bacteria
of Escherichia coli O157:H7, Salmonella typhimurium and Vibrio parahaemolyticus, successful
multiplexed colorimetric detection was demonstrated. However, the sensitivity of this
colorimetric-based microfluidic approach is not high. The LOD of Escherichia coli O157:H7 was
23

observed as 380 genomic DNA copies. Additionally, an oven is needed as a heating resource for
LAMP reactions.
Fang et al. developed a microfluidic device integrated with LAMP for simultaneous
detection of multiple bacteria. The detection results can be achieved by the naked eye based on the
generated fluorescence of calcein. The LOD of 270 copies genomic DNA for Mycobacterium
tuberculosis was demonstrated.125 However, the bacteria lysis and DNA extraction procedures are
complicated to operate.
By monitoring the fluorescence signals from a fluorescent DNA binding dye (SYTO-82)
using an imaging system, Tourlousse et al. performed LAMP on a microfluidic device for
multiplexed foodborne pathogen detection.140 The microfluidic device contains an array of 15
interconnected reaction wells with dehydrated LAMP primers, and integrates microvalves and
hydrophobic air vents using an inexpensive knife plot to improve robustness of loading and
amplification. Rapid analysis of multiple virulence and marker genes of Salmonella, Shigella,
Campylobacter jejuni and Vibrio cholerae was achieved, enabling detection and quantification of
10-100 copies/μL in less than 20 minutes. However, the fabrication of the microvalves increases
the complexity of the microfluidic device.
Fang et al. reported an octopus-like multiplex microfluidic LAMP assay for the rapid
analysis of multiple genes for predicting viruses.141 An optical detection unit included commercial
optical fibers and a digital fiber optical sensor was coupled with the microfluidic chip to measure
the absorbance of the generated turbidity from LAMP reaction. This assay demonstrated high
specificity and sensitivity in analyzing multiple genes, with LOD of less than 10 copies/μL in 2
μL quantities of sample. However, optical fibers need to be inserted in the microfluidic device
laterally and to be accurately aligned together with the sample chamber, making the whole system
complicated.
A microfluidic multiplex electrochemical LAMP system was reported for diagnosis of
multiple bacteria.142 The electrochemical signal of methylene blue was measured and analyzed
through eight laser etched indium tin oxide electrodes to monitor the amplification process within
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45 minutes. The LODs of the three acute upper respiratory tract infections related bacteria
(Mycobacterium tuberculosis, Haemophilus influenza and Klebsiella pneumonia) that were chosen
in this study were 28, 17 and 16 copies/μL, respectively. However, the fabrication of the electrodes
on the microfluidic device is very complicated and also increase the assay cost.
Overall, despite the attractiveness of these on-chip LAMP systems for rapid pathogen
detection,125-133 there are multiple limitations which impose restriction on their applications in lowresource settings. First, some microfluidic devices still require complicated fabrication procedures
because of microvalves and patterned electrodes involved,125, 128 which increase the device cost as
well. Second, most systems still rely on fairly expensive and bulky detectors (e.g. potentiostats,127
spectrophotometers128-129 and turbidimeters143) and other supporting equipment (e.g. pumps128 and
water baths125, 129) that are not commonly available in resource-poor settings. Third, complicated
sample preparation procedures are also obstacles to POC detection in low-resource settings. For
example, most of the microfluidic device-based LAMP still relies on traditional off-chip sample
preparation, requiring the use of centrifuges and water bath in a laboratory setting,127 and timeconsuming producers including bacterial cell lysis, multiple washing steps, and elution.137-138
Some microfluidic devices coupled with nucleic acid extraction unit by using magnetic beads or
FTA membranes to perform on-chip LAMP. However, both the magnetic bead-based and the FTA
membrane-based sample preparation still require complicated procedures such as bacterial cell
lysis, nucleic acid hybridization on beads, multiple washing steps, and elution.128
1.3.2 Nucleic acid hybridization on microfluidic devices
Nucleic acid hybridization is a phenomenon or technique in which ssDNA or RNA interact
and anneal to their complementary DNA or RNA sequences. Nucleic acid hybridization can be
used to identify target nucleic acid (DNA or RNA) samples, aiding the genetic diagnosis and
infectious disease diagnosis.144
Nucleic acid hybridization can be performed on various substrates (e.g. glass, PDMS,
PMMA). However, those substrates require laborious, complicated and long-time surface
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modifications and coating procedures.145-148 As a low-cost, portable, disposable and fast nucleic
acid analysis method, microfluidic paper-based nucleic acid hybridization has attracted great
interest among researchers for clinical diagnosis and research. Optical assays including
colorimetric and fluorescent detection, and electrochemical assays are the common methods used
for nucleic acid hybridization on paper-based microfluidic devices.
Araújo et al. developed a paper strip with cellulose surfaces immobilized by 1,4phenylenediisothiocyanate (PDITC) and bearing ssDNA probe for rapid target hybridization.149
The schematic is illustrated in Figure 1.4. The Whatman No. 1 filter paper was immobilized by
using a bifunctional linking reagent, PDITC, making it amenable to the subsequent coupling of
ssDNA probe. The intrinsic wicking ability of the paper matrix facilitated rapid hybridization with
the target complementary Cy3-labelled ssDNA samples that generated from the PCR amplicons
after treatment. By the discrimination of amplicons generated from canine and human
mitochondrial and genomic DNA in mock forensic samples, the paper strip for rapid and specific
DNA diagnostics was successfully exemplified. Although rapid hybridization process is
demonstrated (2 minutes), this approach is time-consuming for immobilization of the filter paper
with PDITC (>12 hours), laborious and complicated for generation of ssDNA from PCR
amplicons, and cannot achieve multiplexed detection. In addition, multiple washing steps are
involved in both the paper immobilization process and the hybridization process.
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Figure 1.4: Schematic illustration of a cellulose surfaces activated paper-based strip for DNA
immobilization and subsequent rapid hybridization. Step 1-3: cellulose surfaces
activation with PDITC, immobilization of aminated ssDNA probes, and
hybridization with complementary Cy3-labeled ssDNA, respectively. (Source:
Adapted with permission from Araújo et al., 2012. Copyright © 2012 American
Chemical Society.149)
Cheng et al. presented a paper-based microfluidic device for colorimetric assay of dengue
fever by monitoring dengue virus serotype 2 RNA at the molecular level.150 The paper-based
microfluidic device consisted of 96 wells that were fabricated via wax printing. The target dengue
virus serotype 2 RNA was amplified using reverse transcription LAMP (RT-LAMP) with the
addition of biotin-labeled dUTPs. The amplicons would then be detected through conjugating
biotin-labeled dUTPs with streptavidin which was linked with a specific enzyme horseradish
peroxidase (HRP) on the paper-based microfluidic devices. A colorimetric assay was finally
achieved with a color change from colorless to blue via the enzyme reaction by using the enzyme
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substrates (3, 3’, 5, 5’-tetramethylbenzidine and R2O2). The results were further processed with
image analysis (ImageJ) for quantitative analysis. The paper-based microfluidic colorimetric assay
was capable of detecting the amplicons with the concentration of 300 ng/mL. Although paper
immobilization and amplicon treatment are not required, multiple washing steps are still needed
in this microfluidic approach. Additionally, detection results would be significantly influenced by
the amount of HRP-streptavidin and the washing conditions.
Electrochemical nucleic acid hybridization on paper-based microfluidic devices is highly
sensitive (e.g. picomolar or femtomolar level).151-152 However, complicated immobilization
process for electrodes and ssDNA probes and multiple washing steps are usually required.
Additionally, bulky instruments are needed in a laboratory setting for detection of electrochemical
signals, which further limits the applications of the electrochemical nucleic acid hybridization on
paper-based microfluidic devices for POC analyses.
Overall, although the good performance of the paper-based microfluidic DNA
hybridization and detection could be achieved, it still relies on an off-chip nucleic acid
amplification process, involves complicated surface modification process and multiple washing
steps, and often requires expensive and bulky equipment in laboratory settings for support.
Because of the issues of liquid evaporation and heating element requirements, it is still challenging
to integrate nucleic acid amplifications on paper-based microfluidic devices for nucleic acid
hybridization.
1.4

Research objectives
The goal of this research is to provide low-cost microfluidic POC diagnostic platforms for

rapid and sensitive infectious disease diagnosis in low-resource settings.
Taking advantages of microfluidic lab-on-a-chip and LAMP, we have developed three lowcost paper/polymer hybrid microfluidic biochips integrated with LAMP for infectious disease
diagnosis including bacterial meningitis and pertussis. The organization structure of this
dissertation can be seen in Figure 1.5.
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Chapter 3 introduces a versatile paper/PDMS hybrid microfluidic biochip for detection of
a main meningitis-causing bacterium, N. meningitidis. Based on the generated fluorescence signal
under a portable UV light pen, the detection results could be easily achieved by the naked eye
without using any specialized laboratory instrument. Moreover, the confirmation and quantitative
results could be further obtained in a laboratory setting. Paper inside this hybrid microfluidic
biochip served as a 3D substrate for storage and preservation of the DNA primers, which enabled
stable testing results over three months. The LOD of 3 copies per LAMP zone for N. meningitidis
was achieved within 45 minutes. By using a simple centrifuge-free and LAMP-compatible
microorganism lysis process, the direct detection of pathogenic microorganisms was successfully
achieved without laborious sample preparation process or the use of centrifuges.
We further demonstrated the broader application of our microfluidic approach for detection
of the whooping cough-causing bacterium, B. pertussis, which is introduced in Chapter 4. Within
45 minutes, the LOD of 5 copies per LAMP zone for B. pertussis was achieved without using any
specialized instruments. High specificity and high sensitivity of the microfluidic approach were
demonstrated by testing 100 human clinical samples, which were comparable with the costly qPCR
test.
Multiple pathogens could coexist in some cases and the identification of the exact pathogen
is important because the treatment and antibiotics differ from each other. But multiplexed pathogen
detection is challenging for traditional tube-based LAMP method. Therefore, by performing
parallel LAMP reactions in independent compartments, Chapter 5 introduces another low-cost
paper/PDMS hybrid microfluidic biochip for instrument-free multiplexed pathogen detection. In
this work, simultaneous detection of N. meningitidis, S. pneumoniae and Hib, three common
pathogens that cause most of the bacterial meningitis, were successfully demonstrated. LODs of a
few copies of initial template DNA per LAMP zone for each pathogen were rapidly achieved.
Multiplex LAMP (mLAMP) detection is challenging to achieve since the traditional gel
electrophoresis assisted detection method is not effective. Therefore, in Chapter 6, we introduce a
paper/PMMA hybrid CD-like microfluidic SpinChip integrated with ssDNA probe-functionalized
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GO nanosensors for mLAMP detection of N. meningitidis and S. pneumoniae. The probefunctionalized nanosensors allowed a simple and highly specific on-chip quantitative analysis of
mLAMP products. LODs were as low as 6 and 12 copies per assay for N. meningitidis and S.
pneumoniae, respectively. Paper inside this hybrid SpinChip facilitated the simple integration of
probe-functionalized nanosensors without any complicated surface modifications or treatment.
This work provides a simple and effective microfluidic approach for quantitative mLAMP
detection.
Chapter 7 presents concluding remarks and future directions of the research work.
In summary, the low-cost paper/polymer hybrid microfluidic biochips that we developed
have great potential for POC diagnosis of a wide range of infectious diseases, especially in lowresource settings such as developing countries where financial and medical resources are
extremely limited.

30

Figure 1.5: The structure of this dissertation.
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Chapter 2: Experimental



This chapter introduces chemicals and materials used in the research projects.



Bacterial culture and DNA preparation procedures, and fabrication of paper/polymer
hybrid microfluidic biochips are described in this chapter.



The instrumentation and data analysis are demonstrated in this chapter.



DNA quantitation by Nanodrop and gel electrophoresis confirmatory test are introduced in
this chapter.

32

2.1

Chemicals and materials
LAMP kit and fluorescence detection reagent: LAMP DNA amplification kit and LAMP

fluorescence detection reagent (calcein) were purchased from Eiken Co. Ltd., Japan. The LAMP
reaction mixture contained 20 mM Tris-HCl (pH 8.8), 10 mM KCl, 8 mM MgSO4, 10 mM
(NH4)2SO4, 0.1% Tween 20, 0.8 M Betaine, 0.5 mM MnCl2, 1.4 mM dNTPs, 8U Bst Polymerase,
1.6 μM each of the inner primer (FIP/BIP), 0.2 μM each of the outer primer (F3/B3), 0.4 μM each
of the loop primer (LF/LB). All the LAMP primers and ssDNA probes were produced by
Integrated DNA Technologies, Coralville, IA.
DNA purification kit: DNA isolation kit and LAMP products purification kit were
purchased from Qiagen (Valencia, CA).
Bacterial lysis buffer: Bacteria lysis buffer contained 50 mM Tris buffer (pH 7.5), 4 M urea
and 0.1% triton.
Microfluidic biochip fabrication materials: The liquid PDMS base and the curing agent
(Sylgard 184) were obtained from Dow Corning (Midland, MI). PMMA was purchased from
McMaster-Carr (Los Angeles, CA); graphene oxide was purchased from Graphene Laboratories
(Calverton, NY); Whatman #1 chromatography paper and Epoxy glue were purchased from Sigma
(St. Louis, MO) and ITW Devon (Danvers, MA), respectively.
All other chemicals were purchased from Sigma (St. Louis, MO) and used without further
purification. Unless otherwise noted, all solutions were prepared with ultrapure Milli-Q water
(18.2 MΩ cm) from a Millipore Milli-Q system (Bedford, MA).
2.2

Bacterial culture and template DNA preparation

2.2.1 Bacterial culture
Bacterial culture was performed on streaked agar plates to obtain single colonies of bacteria
for the subsequent DNA preparation or artificial clinical sample preparation. General procedures
are as follows:
(1) Obtain an appropriate agar plate for the target bacteria.
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(2) In a sterile biosafety cabinet, label the bacteria name and date on the bottom of the agar
plate.
(3) Add sterile supplements into the agar plate if necessary, and wait to dry.
(4) Obtain a bacteria bead from the stock by using a sterile loop.
(5) Spread the bacteria bead gently to create streak (a) over a section of the agar plate, as
shown in Figure 2.1.
(6) Drag through streak (a) and spread the bacteria gently to create streak (b) over another
section of the agar plate (Figure 2.1).
(7) Drag through streak (b) and spread the bacteria gently to create streak (c) over the left
section of the plate (Figure 2.1).
(8) Incubate the fresh bacteria plated agar plate. The incubation conditions (e.g.
temperature, humidity, CO2 concentration, et al.) and incubation time should vary with the target
bacteria.
(9) Check if single bacterial colonies are formed and ready to use.

Figure 2.1: Schematic of streaking for a single colony in bacterial culture.
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Bacterial meningitis culture
The N. meningitidis (ATCC 13098), S. pneumoniae (ATCC 49619) and H. influenzae
(ATCC 33533) were obtained from American Type Culture Collection (ATCC, Rockville, MD).
N. meningitidis and H. influenzae were grown on Chocolate II agar plates (BD, Sparks, MD). S.
pneumoniae was grown on TSA II agar plates supplemented with 5% sheep blood (BD, Sparks,
MD). All the microorganisms incubated at 37 °C for 48 h in an aerobic environment with 5% CO2.
B. pertussis culture
B. pertussis (ATCC 9797) was obtained from American Type Culture Collection (ATCC,
Rockville, MD), which was grown on Regan-Lowe charcoal agar plates (BD, Sparks, MD)
supplemented with casamino acid. The microorganisms were incubated in an aerobic environment
with sufficient humidity and with 5% CO2 at 37 ℃ for 3-4 days.
2.2.2 Template DNA preparation
DNA was extracted and purified by using the Qiagen DNA Mini kit following a slightly
modified protocol from the manufacturer. Basically, the procedures of DNA preparation for gramnegative bacteria (e.g. N. meningitidis, Hib, and B. pertussis) are as follows:
(1) Swap several single colonies (maximum 2 × 109 cells, adjusted with 0.5 turbidities
McForland) from the culture plate and mix with 5 mL sterile saline placed in a sterile 15 mL
centrifuge tube.
(2) Centrifuge the tube at 5000 × g (7500 rpm) for 10 minutes. Discard the supernatant.
(3) Resuspend the bacterial pellet in a mixture solution containing 180 μL lysis buffer ATL
and 20 μL proteinase K (600 mAU/mL). Transfer the liquid into a sterile 1.5 mL microcentrifuge
tube.
(4) Incubated the microcentrifuge tube at 56 °C in a water bath for 1-3 hour. Vortex the
microcentrifuge tube occasionally during the incubation to disperse the sample.
(5) Add 200 μL buffer AL to the sample, and mix thoroughly by vortex. Then add 200 μL
ethanol, and mix thoroughly by vortex.
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(6) Pipet the mixture including any precipitate into a column placed in a 2 mL collection
tube. Centrifuge at 6000 × g (8000 rpm) for 1 minute. Discard flow-through.
(7) Add 500 μL buffer AW1, and centrifuge at 6000 × g (8000 rpm) for 1 minute. Discard
flow-through.
(8) Add 500 μL buffer AW2, and centrifuge at 20000 × g (14000 rpm) for 3 minutes.
Discard flow-through.
(9) Centrifuge again at 20000 × g (14000 rpm) for 1 minute for 1 minute. Place the column
in a clean 2 mL microcentrifuge tube.
(10) Add 200 μL buffer AE to the center of the column membrane and incubate at room
temperature for 1 minute. Then centrifuge the column placed in the microcentrifuge tube at 6000
× g (8000 rpm) for 1 minute to elute DNA. Then the purified DNA are collected in the
microcentrifuge tube for use.
DNA preparation for gram-positive bacteria (e.g. S. pneumoniae) is following the similar
procedures stated above. However, procedures (3) to (5) should be modified as follows:
(3) Resuspend the bacterial pellet in 180 μL enzymatic lysis buffer (20 mM Tris·Cl, pH
8.0; 2 mM sodium EDTA; 1.2% Triton X-100; adding lysozyme to 20 mg/mL immediately before
use).Transfer the liquid into a sterile 1.5 mL microcentrifuge tube and incubate at 37 °C for at least
30 minutes. After that, add 25 μL proteinase K (600 mAU/mL) and 200 μl buffer AL, and mix
thoroughly by vortex.
(4) Incubated the microcentrifuge tube at 56 °C in a water bath for 30 minutes.
(5) Add 200 μL ethanol to the sample, and mix thoroughly by vortex.
2.3

Fabrication of paper/polymer hybrid microfluidic biochips

2.3.1 Paper/PDMS hybrid microfluidic biochips
The standard soft lithography procedures were followed to produce PDMS films.153 Firstly,
the liquid PDMS base and the curing agent mixture were prepared at a weight ratio of 10:1. Then
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the PDMS precursor mixture was poured into a petri dish, which was degassed in a vacuum
desiccator for ~30 minutes and incubated in an oven at 85 °C for 2.5 hours.
Unlike the commonly used PDMS molding, microchannels were directly created on the
surface of PDMS films via ablation using a laser cutter (Epilog Zing 16, Golden, CO). Inlet
reservoirs, outlet reservoirs, and LAMP zones were excised using different sizes of biopsy
punches. A chromatography paper disk cut by a laser cutter (Epilog Zing 16, Golden, CO) was
placed inside each LAMP zone, as a 3D storage substrate for specific LAMP primers. After 30
seconds exposure in an oxidizing air Plasma Cleaner (Ithaca, NY), PDMS films and the glass slide
were face-to-face sandwiched to bond irreversibly. Thus, the assembled paper/PDMS hybrid
microfluidic biochips became ready for use.
2.3.2 Paper/PMMA hybrid microfluidic SpinChip
All the LAMP zone, detection wells, inlet, and the paper disks were directly cut by a laser
cutter (Epilog Zing 16, Golden, CO) within minutes. The bottom plate was exposed in an oxidizing
air Plasma cleaner (Ithaca, NY) for 30 seconds, making the LAMP zone hydrophilic. The
chromatography paper inside the detection wells absorbed GO and ssDNA probe solutions through
the capillary effect. First, 0.8 μL of 0.04 mg/mL GO prepared in water was added into each
detection well. After it became dry in 5 min at room temperature, 0.8 μL ssDNA probe solution
was then added into each detection well and was left to dry at room temperature for 5 min. The
two plates were then tightened together with a screw in the center of both plates. As a result, the
hybrid microfluidic SpinChip became ready-to-use.
2.4

Instrumentation and data analysis

2.4.1 Cellphone and gray values
A portable UV pen light was applied to shine LAMP products on the biochips after onchip LAMP reactions to obtain the visual detection results. The generated fluorescence was
captured by a cellular phone camera (e.g. iPhone 5) under a portable UV light pen, as shown in
Figure 2.2.
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The cellphone camera captured images were processed with an NIH software ImageJ to
obtain the gray values of the LAMP products in each LAMP zone and the negative controls (see
Figure 2.2). The gray value is used to indicate the brightness of the measured areas of an image.

Figure 2.2: Schematic of the cellphone-based detection system.
2.4.2 Fluorescence microscope and fluorescence intensities
A high-sensitivity Nikon Ti-E fluorescence microscope (Melville, NY) was employed for
fluorescence detection and confirmation. The schematic of the fluorescence microscope detection
system is shown in Figure 2.3. The fluorescence microscope was equipped with a motorized stage
and a cooled charge-coupled device (CCD) camera. Appropriate FITC optical filters (Ex = 495
nm; Em = 520 nm) was used for the fluorescence detection of calcein, and Cy3 optical filters (Ex
= 550 nm; Em = 570 nm) was used for the fluorescence detection for Cy3-labelled primers and
ssDNA probes. Fluorescence intensities were measured with the microscope scanned images.
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Figure 2.3: Schematic of the fluorescence microscope based detection system.
2.5

DNA quantitation by Nanodrop
The nucleic acid concentration of the template DNA and the LAMP products of 1 µL

samples were measured by using Nanodrop (Nanodrop 1000, Thermo Scientific, MA). The LAMP
products were purified by using the Qiagen amplicon purification kit in advance. The general
procedures are as follows: (1) Mix 5 μL of the LAMP products to 25 μL buffer PB. (2) To bind
nucleic acids, apply the mixture to a column placed in a 2 mL collection tube and centrifuge at
17900 × g (13000 rpm) for 1 minute. Discard the flow-through. (3) To wash, add 750 μL buffer
PE to the column and centrifuge at 17900 × g (13000 rpm) for 1 minute. Discard the flow-through.
(4) To remove residual wash buffer, centrifuge again at 17900 × g (13000 rpm) for 1 minute. Put
the column in a clean 2 mL microcentrifuge tube. (5) To elute nucleic acids, add 50 μL buffer EB
(10 mM Tris·Cl, pH 8.5) to the center of the column membrane and centrifuge at 17900 × g (13000
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rpm) for 1 minute. The purified LAMP products are then collected in the microcentrifuge tube for
further quantitation analysis by Nanodrop.
The calculation of determining the copy numbers of the template DNA is based on the
estimation that one mole of a base pair (bp) weighs 650 g (assuming the average weight of a bp is
650 Daltons). Therefore, the copy numbers of the template DNA = (amount × 6.022 × 1023) /
(length × 650) = (g × number/mol) / (bp × g/mol of bp).154
2.6

Gel electrophoresis confirmatory test
LAMP products were collected for further confirmatory tests using a conventional gel

electrophoresis (Sub-Cell GT, Bio-Rad, CA). During the gel electrophoresis, amplified products
were resolved by applying 90 V for 1 hour in 1.5% agarose gel.
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Chapter 3: A Versatile Paper/PDMS Hybrid Biochip for Meningococcal
Diagnosis

Reproduced in part with permission from the American Chemical Society.


Parts of this chapter were published in Analytical Chemistry as a research article in 2014.
(M Dou, DC Dominguez, XJ Li, J Sanchez, G Scott. Analytical Chemistry, 2014, 86, 79787986.)



This chapter introduces a versatile paper/PDMS hybrid microfluidic biochip for diagnosis
of a main meningitis-causing bacterium, N. meningitidis.



Paper in this hybrid biochip serves as a 3D substrate for storage of LAMP primers and
enables a stable diagnostic performance for a long period of time.



A rapid and sensitive qualitative detection result can be visualized by the naked eye without
using any specialized instruments; further confirmatory diagnosis or quantitative analysis
can be achieved using the amplicons from the versatile biochip in a laboratory setting.



The meningitis diagnosis on a low-cost microfluidic biochip was achieved for the first time
for POC testing for low-resource settings.
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3.1

Introduction
Infectious diseases frequently cause public human health concern worldwide and cause an

extremely significant impact on global health and economies.1-2 Among various global infectious
diseases, epidemic bacterial meningitis, a severe infection affecting the protective membranes
covering the brain and spinal cord known as the meninges, is one of the most dangerous diseases
due to its high morbidity and mortality, as described in Section 1.1.1. Meningitis can become fatal
in as early as 24 hours after symptoms are noticed. Additionally, many meningitis cases occurred
in rural high-poverty areas, such as the so-called “meningitis belt” in Africa, where it remains an
important and unresolved public health concern with recurrent unpredictable epidemics.
N. meningitidis, the etiologic agent of the meningococcal disease, is a leading cause of
morbidity and mortality in children and young adults worldwide.155-156 It is also a dominant
etiologic bacterium in the “meningitis belt” of sub-Saharan Africa according to the bacteriologic
and epidemiologic data collected over the past 30 years.157-158 Usually patients with meningitis
share symptoms common to many febrile illnesses (e.g. influenza), which makes meningitis
difficult to diagnose based on clinical symptoms alone. Given that meningitis can be fatal and
many meningitis cases occurred in high-poverty areas, a simple, low-cost, a highly sensitive
method is in great need for immediate and early diagnosis of meningitis.
There are several laboratory guidelines available from the Centers for Disease Control and
Prevention (CDC) and the WHO for the diagnosis of meningitis. However, as described in Section
1.1.3, the current technologies for meningitis diagnosis have their own limitations. Gram stain and
bacterial culture appear to be the gold standard.18 However, both have to be done in a laboratory
setting, and bacterial culture may take a few days. Although gram stain may aid in providing a fast
identification after reaching the laboratory, it still has many limitations. (1) Gram stain has a lower
detection rate for patients previously treated with antimicrobial therapy. (2) Its detection sensitivity
is low. (3) It requires well-trained personnel, due to the fact that sometimes poor staining occurs.26
Recently, qPCR and LAMP have been reported to provide rapid detection of bacterial
meningitis.35, 46 However, these methods require specialized equipment in laboratories, such as
42

qPCR thermocyclers (~$60,000), turbidimeters, centrifuges, fluorescent microscopes, and so on,
which render these methods incapable of rapid diagnosis of meningitis in the field or in lowresource settings.
As mentioned in Section 1.2.1, microfluidic lab-on-a-chip offers a unique opportunity for
various biomedical applications due to a variety of advantages associated with miniaturization,
integration, portability and automation.61,

159-163

It allows for significantly low reagent

consumption, integrated processing and analysis of complex biological fluids with high efficiency
and sensitivity in health care settings, as well as the possibility of rapid detection. As mentioned
in Section 1.2.2, the substrates of a microfluidic device can significantly affect many aspects of a
microfluidic system from fabrication methods, cost, assay procedures, to detection. Various
materials including Si,164 glass,165-169 PDMS129,

170-171

and paper172-175 have been used for

microfluidic device fabrication. However, as discussed in 1.2.3, each substrate material has its own
advantages and limitations. For instance, PDMS microfluidic devices are used extensively for
biomedical applications, because of its moderate cost and ease of microfabrication (termed as soft
lithography171) and transparent property for optical detection. However, PDMS devices often
require complicated surface modification procedures to immobilize biosensors on a chip. Recently,
paper-based microfluidic devices afford a new low-cost platform for different applications related
to health care in low-resource settings.174-176 Paper-based devices, however, do not offer the high
performance in flow control found in PDMS devices. Therefore, the Li group previously developed
a paper/PDMS hybrid microfluidic system (see Section 1.2.3), in which paper facilitated the
integration of aptasensors on the microfluidic system without any complicated surface
treatment.116
Recently, microfluidic chips integrated with LAMP reactions have been developed for
rapid pathogen detection. However, as discussed in Section 1.3.1, there are multiple limitations
that impose a restriction on their applications in low-resource settings, such as requiring
complicated fabrication and assay procedures, relying on fairly expensive and bulky detectors and
other supporting equipment. 125, 128
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As far as we know, no low-cost microfluidic POC devices have been reported for the rapid
diagnosis of meningitis in low-resource settings. Herein, we report a novel versatile and low-cost
paper/PDMS hybrid microfluidic platform for the rapid, sensitive, and instrument-free detection
of N. meningitidis.177 Chromatography paper used in this hybrid system serves as a 3D substrate
for the pre-storage of DNA primers for subsequent LAMP reactions to improve the detection
sensitivity. The detection of N. meningitidis is highly sensitive, with a LOD of about 3 template
DNA copies per LAMP zone achieved. To our best knowledge, this is the lowest LOD from
reported on-chip LAMP systems for detection of N. meningitidis.
This hybrid microfluidic biochip was designed to offer versatile functions. First, a rapid
qualitative detection result (i.e. giving a yes or no answer) of N. meningitidis can be achieved
within 45 minutes without using any specialized instruments. Results can be visualized by the
naked eye. These features make the microfluidic biochip capable of quick preliminary diagnosis
of meningitis in the field or other resource-limited settings. Furthermore, on-chip LAMP products
can be readily collected for confirmatory diagnosis or quantitative analysis of meningitis in a
laboratory setting.
3.2

Experimental section

3.2.1 Chemicals and materials
The LAMP primers for the target ctrA gene sequences of Neisseria meningitidis are shown
in Table 3.1.46
Table 3.1: LAMP primer sequences for ctrA gene of N. meningitidis
Primer
FIP
BIP
F3
B3
FL
BL

Sequences (5’-3’)
CAAACACACCACGCGCATCAGATCTGAAGCCATTGGCCGTA
TGTTCCGCTATACGCCATTGGTACTGCCATAACCTTGAGCAA
AGC(C/T)AGAGGCTTATCGCTT
ATACCGTTGGAATCTCTGCC
CGATCTTGCAAACCGCCC
GCAGAACGTCAGGATAAATGGA

All the other chemicals and materials are listed in Section 2.1.
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No. of bases
41
42
19
20
18
22

3.2.2 Bacterial culture and DNA preparation
The bacterial culture and DNA preparation protocols for N. meningitidis are described in
Section 2.2. The calculation of determining the copy numbers of the N. meningitidis template DNA
is demonstrated in Section 2.5.
3.2.3 Microfluidic biochip design and fabrication
As shown in Figure 3.1, the microfluidic biochip comprises three layers, namely two
PDMS layers on the top of a glass slide. The top layer is the PDMS layer used for reagent delivery,
including three microchannels (width 100 µm, depth 100 µm) on the bottom side of the PDMS
layer, and one inlet reservoir (diameter 1.0 mm, depth 1.5 mm). The middle PDMS layer consists
of 6 wells as LAMP zones (diameter 2.0 mm), 3 outlet reservoirs (diameter 1.0 mm) and microchannels (width 100 µm, depth 100 µm) at the bottom side of the middle PDMS layer to connect
to outlet reservoirs. The bottom layer is a glass slide mainly for structure support.
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Figure 3.1: Layout of the versatile paper/PDMS hybrid microfluidic biochip. (a) 3D illustration.
(b) A photograph. (c) A cross-section view of the LAMP zone illustrating the
principle of the LAMP detection.
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A Whatman #1 chromatography paper disk (diameter 2.0 mm) was placed inside each
LAMP zone, as a 3D storage substrate for LAMP primers. Different LAMP zones were used for
negative control (NC), positive control (PC) and N. meningitidis detection, respectively. The
omission of LAMP primers (NC1) was adopted as the main NC for the convenience of reagent
and sample delivery, which demonstrated consistent results with another type of NC with the
omission of template DNA (NC2) (see Figure 3.5 for more information). PC DNA and its primer
mix were provided by the commercial LAMP kit.
Fabrication of the microfluidic biochip was described in Section 2.3.1.
3.2.4 On-chip LAMP procedures
After a 26 μL LAMP mixture was prepared in a biosafety cabinet, the LAMP reaction
mixture was introduced into the biochip from the inlet reservoir to fill different LAMP zones. After
the inlet and outlets reservoirs were sealed with Epoxy glue, the microfluidic biochip was placed
on the heating film at 63 °C for 45 minutes for LAMP reactions, followed by the termination of
LAMP reactions at 95 °C for 2 minutes.
The heating film was controlled by an inexpensive portable proportional–integral–
derivative (PID)-based temperature controller which was devised by our research group, as can be
seen in Figure 3.2. The material cost of this whole heating unit was about $60.
The principle of the LAMP detection is shown in a cross-section view of the LAMP zone
(see Figure 3.1c). The fluorescence of calcein is quenched by manganese ions before the LAMP
reaction. When the amplification reaction proceeds, the byproduct pyrophosphate ions form the
complex with manganese ions. As a result, calcein is free to combine magnesium ions, which
results in the emission of bright fluorescence under UV light.44, 178 The generated fluorescence was
captured by a cellular phone camera (e.g. iPhone 5), and the images were processed with the NIH
software ImageJ, as described in Section 2.4.1. Results were further confirmed by a highsensitivity Nikon Ti-E fluorescence microscope (Melville, NY) that was equipped with a
motorized stage and a cooled CCD camera to measure the fluorescence intensities, using
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appropriate FITC optical filters (Ex = 495 nm; Em = 520 nm) for calcein and Cy3 optical filters
(Ex = 550 nm; Em = 570 nm) for Cy3-labelled primers, as described in Section 2.4.2.

Figure 3.2: A photograph of the portable heater. A penny was included in this photograph for
size comparison.
3.2.5 Post-chip analysis
LAMP products were collected from each outlet of the microfluidic device for further
confirmatory tests using conventional gel electrophoresis, as described in Section 2.6. DNA
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quantitative analysis of collected LAMP products was carried out using Nanodrop, as described in
Section 2.5.
3.2.6 Centrifuge-free detection of microorganisms
ACSF buffer preparation: Artificial cerebrospinal fluid (ACSF) buffer was prepared
according to previously published protocol.179 The ACSF buffer contained 119 mM NaCl, 26.2
mM NaHCO3, 2.5 mM KCl, 1 mM NaH2PO4, 1.3 mM MgCl2, 10 mM glucose. It was bubbled
with 5% CO2/95% O2 for 10-15 minutes before CaCl2 was added to the buffer to reach a final
concentration of 2.5 mM CaCl2. The prepared ACSF buffer was filtered with a 0.20 µm filter
apparatus and stored at 4 °C before use.
Centrifuge-free assay procedures for microorganisms in ACSF were as follows: First, a
tiny amount of N. meningitidis bacteria colonies from the culture plate were swabbed by using an
inoculation loop and suspended in 1 mL ACSF buffer to prepare the pathogen/ACSF mixture by
adjusting the turbidity to McFarland Standard 0.5 (Key Scientific Products, TX) to have an
approximate bacterial density of 1.5 × 108 CFU/mL.180 Then 2 μL of this mixture was added into
an 18 μL bacterial lysis buffer that contained 50 mM Tris buffer (pH 7.5), 4 M urea and 0.1%
triton, and incubated at room temperature for 10 minutes. At last, 2 μL of the pathogen/pathogen
mixture lysate was used in the LAMP reaction mixture for on-chip LAMP reaction, as performed
in the aforementioned on-chip LAMP procedures.
3.3

Results and discussion

3.3.1 Paper/PDMS hybrid microfluidic biochip
Because different chip substrates have their own advantages and limitations, the Li group
previously developed a paper/PDMS hybrid microfluidic system for one-step pathogen detection,
in which paper facilitated the integration of aptasensors on the chip, as described in Section
1.2.3.116 Although this method can directly measure microorganisms without complicated sample
preparation due to the use of aptamers, the sensitivity is generally not as high as nucleic acid
amplification-based methods. In this work, chromatography paper is placed in LAMP zones to
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form another paper/PDMS hybrid microfluidic biochip, in which paper serves as the 3D substrate
for pre-loading DNA primers for subsequent LAMP reactions to improve detection sensitivity.
The paper is a highly porous material, which renders it as an ideal 3D storage substrate for
interaction-based assays.181 Paper’s 3D microstructures can also facilitate uniform reagent
distribution. It can be seen from Figure 3.3 that when fluorescently-labeled primers (10.4 μM)
were initially loaded into LAMP zones, primers were uniformly distributed in LAMP zones either
with paper or without paper inside (Figure 3.3a). However, when biochips were placed in a vacuum
desiccator to dry, a necessary step to make a ready-to-use POC device in this work, primers in
paper-free LAMP zones accumulated on the edge of the LAMP zones, while primers in LAMP
zones with paper inside were still uniformly distributed (Figure 3.3b).
Using the detection of N. meningitidis as an example, the on-chip LAMP performance of
the hybrid biochip with paper inside and the non-hybrid biochip without paper inside was
investigated and compared over a period of 3 months. By pre-loading the DNA primers of N.
meningitidis in LAMP zones of the biochips with paper and without paper inside, a series of these
two different kinds of ready-to-use biochips were prepared and stored in dark at room temperature
under the same conditions. To evaluate the on-chip LAMP performance, LAMP products from
different hybrid and non-hybrid biochips were quantified by using Nanodrop for each LAMP
reaction after different time periods (in 0.5, 1.0, 1.5, 2 and 3 months, respectively). As shown in
Figure 3.3c, the LAMP performance of the non-hybrid biochip decreased sharply within the first
two weeks (by ~22%), and kept decreasing through the whole experimental period, with a decrease
of ~40% after 3 months. It indicated that without paper inside, the non-hybrid microfluidic biochip
was not able to provide consistent performance over a relatively long period of time. Fresh devices
should be prepared right before the LAMP assay, making them user-unfriendly and inappropriate
for in-field and POC applications. On the contrary, the LAMP performance of the hybrid biochip
with paper inside remained stable over the experimental period. Only a slight decrease (~6%) was
observed within the first 2 months. And the on-chip LAMP performance remained stable even
after 3 months (>85%). Therefore, our hybrid biochip with the introduction of paper as a primer
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storage substrate enabled more stable on-chip LAMP performance than the paper-free non-hybrid
biochip for a long period time. This is mainly because: (1) Highly interwoven paper fibers can
provide DNA primers a 3D matrix from harsh environmental elements, and thus is commonly used
to collect samples for forensic DNA analysis.182,183 (2) DNA primers can be physically adsorbed
onto paper fibers, avoiding DNA loss in the air in the form of aerosols.
Owens et al. reported a simple and economical filter paper-based method to store and
preserve insect DNA as template for PCR analysis, which showed successful PCR amplification
after 7 months.184 We expect that our hybrid microfluidic biochip with paper inside for storage and
preservation of the pre-loaded DNA primers should have a much longer shelf life than the tested
period of 3 months.
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Figure 3.3: (a-b) Fluorescence images of Cy3-labelled primers in LAMP zones with and without
a paper disk inside. (c) Performance comparison between the hybrid biochip with
paper and the non-hybrid biochip without paper over a period of 3 months.
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3.3.2 On-chip LAMP detection of N. meningitidis using extracted DNA
To offer high-sensitivity detection, DNA amplification is usually required. Although PCR
is the most commonly used DNA amplification method, it requires a carefully controlled sequence
of heating and cooling cyclers. The fabrication of heaters and temperature sensors on a chip is
complicated.68 In contrast, the LAMP method that utilizes the Bst DNA polymerase, a thermallystable enzyme with high displacement ability over the template-primer complex,40-41 is a simple,
rapid, specific and cost-effective nucleic acid amplification method when compared to PCR.185
This isothermal LAMP DNA amplification technique allows nucleic acid amplification to be
carried out under thermally constant conditions, eliminating the use of expensive instrumentation
(e.g. thermal cyclers) for stringent thermal cycling as in conventional PCR, or complicated and
costly microfabrication of heating elements on a chip for on-chip PCR.68
The feasibility of the paper/PDMS hybrid microfluidic biochip for N. meningitidis
detection was first tested by using extracted DNA of N. meningitidis. The N. meningitidis DNA
was extracted from bacterial culture. A 26 μL LAMP reaction mixture was introduced through the
inlet reservoir into different LAMP zones, where the specific LAMP primers for the target N.
meningitidis and PC DNA were pre-loaded, respectively. A notable feature of the device design is
that the LAMP reaction wells in the middle PDMS layer were independent without connections in
the same layer, which can effectively prevent cross-talk among the sample test, PC, and NC LAMP
zones during the LAMP reactions.
During the LAMP amplification process, it was observed that a magnesium pyrophosphate
precipitate was formed as a turbid byproduct of the nucleic acid amplification process.186 This
precipitate forms only when the targeted DNA is present in the LAMP amplification process, such
that the presence of the pyrophosphate can serve as an indicator of the presence of a pathogen’s
target DNA by turbidity detection. Turbidity, however, is challenging for high-sensitivity visual
detection. Thus, turbidity detection usually requires a turbidimeter.143
Actually, visual confirmation by the naked eye can be achieved by the addition of a mixture
of calcein in the presence of manganese ions. The fluorescence of calcein is quenched by
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manganese ions before LAMP amplification. When the amplification reaction proceeds, the
manganese-calcein complex is deprived of manganese ions by generated pyrophosphate, which
results in the emission of fluorescence under UV light (see Figure 3.1c).185 As such, clinical
diagnosis of the pathogen N. meningitidis can be achieved by visual confirmation of the bright
fluorescence under a portable UV light pen. As shown in Figure 3.4a, the generated fluorescence
was captured by a cellular phone camera. It was observed that the N. meningitidis sample and PC
showed bright green fluorescence under a portable UV light pen, while the NC1 only showed weak
background. To quantify the difference in the fluorescence between N. meningitidis and NC1, the
gray value, an indication of the brightness of a pixel, of fluorescence images was processed by the
software ImageJ, as shown in Figure 3.4c, which clearly demonstrates the difference between NC1
and PC and N. meningitidis. The results were further confirmed by high-sensitivity fluorescence
microscopy (see Figure 3.4b and 3.4d). Similarly as observed in Figure 3.4a, strong fluorescence
was observed in N. meningitidis and PC LAMP zones, but not in NC1 zones. The fluorescence
intensity of the N. meningitidis LAMP products was about 6 times higher than that of the NC1.
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Figure 3.4: On-chip LAMP detection of N. meningitidis using extracted DNA by a portable UV
light pen (a) and a fluorescence microscopy (b). (c) Gray values measured by
ImageJ; (d) Fluorescent intensities measured by a fluorescence microscope. The
template DNA used was 3 × 106 copies per LAMP zone.
We further tested the on-chip LAMP detection of N. meningitidis by using NC2 with the
presence of LAMP primers and the omission of template DNA. The detection results can be seen
in Figure 3.5, which shows bright fluorescence in LAMP zones for N. meningitidis and PC but not
for NC2. It indicated that both omissions of LAMP primers (NC1) and template DNA (NC2)
showed the same results (see Figure 3.4 and Figure 3.5). Thus NC1 was adopted as the main NC
herein for the convenience of reagent and sample delivery.
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Figure 3.5: A fluorescence image of LAMP products by using extracted N. meningitidis genomic
DNA. The LAMP reaction mixture was introduced from each outlet to fill the
LAMP zones. This NC2 in the presence of primers but not the template DNA
confirmed consistent results from the other type of NC1 in the presence of template
DNA but not the primers which was mostly used in our tests for the convenience of
reagent and sample delivery.
Besides, the multiple-layer biochip is designed in a way to render versatile functions for
the N. meningitidis diagnosis. Because the LAMP zones for N. meningitidis detection, PC, and
NC1 were separated from each other in the middle PDMS layer, different LAMP products can be
simply collected separately for further confirmatory tests using conventional gel electrophoresis
and quantitative analysis in laboratory settings, respectively. When the NC1 reaction mixture and
the N. meningitidis reaction mixture in two PCR tubes were placed under UV light before LAMP
reactions, neither tube showed notable fluorescence (Figure 3.6a). However, after on-chip LAMP
reaction, the collected N. meningitidis LAMP products in a PCR tube showed bright green
fluorescence under UV light (Figure 3.6b). Conversely, the NC1 mixture had no difference after
LAMP reaction. The obvious difference between N. meningitidis tests and NC1 could be seen even
by the naked eye. Subsequently, the results were further confirmed by conventional gel
electrophoresis of extracted LAMP products. The LAMP reaction generates a mixture of stemloop DNA products with various sizes.44 As shown in Figure 3.6c, the comparison of the ladderpattern bands from the LAMP products in lane 2 with the multiple bands from DNA sizing ladder
56

in lane 1 verified the success of the on-chip LAMP. As expected, no bands from the NC1 were
observed in lane 3.

Figure 3.6: Confirmatory analysis of on-chip LAMP products. Collected reaction mixtures in
PCR tubes were placed under a portable UV light pen before (a) and after (b)
LAMP reactions. (c) Gel electrophoresis analysis. Lanes 1-3: 100 bp ladder, N.
meningitidis products, NC1.
3.3.3 Specificity test
As reported previously, LAMP is a reliable method for pathogen diagnosis with high
specificity.187-188 We first tested the specificity of our method among three common types of
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meningitis-causing bacteria, N. meningitidis, H. influenzae, and S. pneumoniae (see Figure 3.7).
All the LAMP zones were pre-loaded with specific primers for N. meningitidis. Different DNA
samples of N. meningitidis, H. influenzae, and S. pneumoniae as well as the NC2 sample (without
template DNA) were introduced with the LAMP reaction mixture from each outlet to fill their
corresponding LAMP zones separately. As shown in Figure 3.7a and 3.7b, signals from LAMP
zones with H. influenzae and S. pneumoniae DNA samples were observed to be similar to NC2.
On the contrary, bright fluorescence from LAMP zones with N. meningitidis DNA sample and its
corresponding primers was observed, which confirmed the high specificity of our approach in the
detection of N. meningitidis. The result was further confirmed by gel electrophoresis of the
collected LAMP products from different LAMP zones. As shown in Figure 3.7c, only the N.
meningitidis LAMP products showed ladder-pattern DNA bands.

Figure 3.7: Specificity study among N. meningitidis, H. influenzae, and S. pneumoniae.
Fluorescence images for specificity test among N. meningitidis, H. influenzae (a)
and S. pneumoniae (b). (c) Gel electrophoresis analysis. Lane 1: 100 bp marker;
Lanes 2-3: products of N. meningitidis and H. influenzae from (a); Lanes 4-5:
LAMP products of N. meningitidis and S. pneumoniae from (b).
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We further used Giardia lamblia (Giardia) as a parasite model and B. pertussis as a bacteria
model to test the specificity of our method for N. meningitidis detection (see Figure 3.8). Giardia
is a common cause of diarrhea in humans and other mammals throughout the world.189 B. pertussis
is the primary etiologic agent of whooping cough.190 Giardia and B. pertussis causing infectious
diseases have some symptoms in common with meningitis, such as nausea, vomiting, diarrhea,
and fever.191-192 Similarly, as shown in Figure 3.8a and 3.8b, after the LAMP reaction, only the
LAMP zones with N. meningitidis DNA sample showed bright fluorescent signal, while LAMP
zone loaded with Giardia and B. pertussis DNA samples showed similar signal to NC2. The results
showed good specificity of our approach for detection of N. meningitidis, which was further
confirmed by gel electrophoresis, as shown in Figure 3.8c.

Figure 3.8: Specificity study among N. meningitidis, Giardia, and B. pertussis. Fluorescence
images for specificity test among N. meningitidis, Giardia (a) and B. pertussis (b).
(c) Gel electrophoresis analysis. Lane 1: 100 bp marker; Lanes 2-3: products of N.
meningitidis and Giardia from (a); Lanes 4-5: LAMP products of N. meningitidis
and B. pertussis from (b).
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3.3.4 Instrument-free detection of N. meningitidis microorganisms
The detection discussed above was carried out by using extracted template DNA. There
have also been reports on rapid PCR detection for clinic samples of pathogenic bacteria by using
special lysis reagents without the inhibition of PCR.68, 193-196 But for LAMP reactions, traditional
sample preparation procedures such as DNA isolation and purification are needed.46-47 These
procedures are time-consuming, and require the use of centrifuges that however usually do not
exist in the field, making them not suitable for POC detection in resource-poor settings.
In this work, we have developed a simple approach for direct pathogenic microorganism
detection (not extracted pathogen DNA). This approach combines a simple bacteria lysis procedure
with on-chip LAMP detection, without using any centrifuge or DNA isolation/purification
procedures. Since the examination of cerebrospinal fluid (CSF) is a cornerstone of current
meningitis diagnosis, we prepared the ACSF samples with spiked N. meningitidis bacteria (~1.5 ×
108 cfu/mL) to mimic the real clinic samples for on-chip LAMP detection.
The first step is to discover a simple method to lysis N. meningitidis microorganisms in a
resource-limited setting. More importantly, the method should be fully compatible to the
subsequent LAMP reactions (i.e. without inhibition to LAMP reactions). We tried various lysis
buffers including some commonly commercial buffers used for PCR (e.g. Buffer ATL from
Qiagen, MagNA Pure Bacteria Lysis Buffer from Roche Applied Science), but found only the lysis
buffer (50 mM Tris buffer (pH 7.5), 4 M urea and 0.1% triton) that we developed is compatible to
LAMP reactions, while others completely inhibited LAMP reactions (see Figure 3.9). This lysis
buffer can be adapted for other microorganism detection using LAMP without problems of
inhibition.
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Figure 3.9: Gel electrophoresis analysis of on-chip LAMP products from N. meningitidis
microorganisms in 2 parallel ACSF samples by using (a) lysis buffer ATL from
Qiagen and (b) MagNA pure bacteria lysis buffer from Roche Applied Science.
Lanes 1-4: 1 kb marker, Sample 1, Sample 2, NC. No ladder-pattern multiple bands
were observed in lane 2 and lane 3, indicating the on-chip LAMP reactions and
direct detection of N. meningitidis microorganisms were unsuccessful by using the
two lysis buffers.
Upon the success of microorganism lysis without the use of any centrifuges, the lysate
without any further preparation was used directly for the on-chip LAMP detection of N.
meningitidis microorganisms in ACSF. The results in Figure 3.10a and 3.10b showed that the
LAMP products of the spiked ACSF sample could still produce strong fluorescence as extracted
DNA samples under the portable UV light and the fluorescence microscope. Figure 3.10c and
3.10d showed good discrimination among spiked the N. meningitidis sample, PC, and NC1. Gel
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electrophoresis of on-chip LAMP products from pathogen/ACSF sample further confirmed the
success of the LAMP reaction (Figure 3.10e), and the successful detection of N. meningitidis.

Figure 3.10: Instrument-free detection of N. meningitidis microorganisms. Fluorescence images
of the on-chip LAMP detection under a portable UV light pen (a) and a
fluorescence microscopy (b). Gray values (c) and fluorescent intensities of the
LAMP products from the ACSF sample. (e) Gel electrophoresis analysis. Lanes 13: 100 bp marker; LAMP products of N. meningitidis from the ACSF sample; NC1.
The instrument-free pathogenic microorganism detection was very simple and fully
compatible with LAMP reactions, without using any equipment such as centrifuges or water baths.
It indicates that real clinical samples could be directly used for the on-chip LAMP reaction and
detection without any laborious and time-consuming DNA isolation or purification procedures.
3.3.5 Calibration curve
The visual LAMP fluorescence detection is a simple method for rapid pathogen detection,
from which a yes/no qualitative answer for POC detection can be achieved quickly based on the
fluorescence of the LAMP products. During our experiments, it was found that the fluorescence
intensity was not directly proportional to pathogen concentrations, indicating the fluorescence
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intensity of calcein is not suitable for quantitative analysis. Although the qualitative analysis was
sufficient for most diseases diagnosis, we developed an indirect method for quantitative analysis
of N. meningitidis based on the versatile functions of the microfluidic chip. A serial of 10-fold
diluted microorganism lysate with DNA copy numbers ranging from 6 × 106 to 6 per LAMP zone
that quantified by Nanodrop in advance was used as the initial template DNA. After the on-chip
LAMP reaction, LAMP products could be simply collected, purified and quantified. Thus, the
calibration was generated by plotting the nucleic acid concentrations of the purified LAMP
products in elution buffer against their initial template DNA copy numbers, as shown in Figure
3.11. It can be seen that the nucleic acid contractions are proportional to the logarithm of the initial
template DNA numbers, with an R2 of 0.98. Therefore, by measuring the nucleic acid
concentration of the purified LAMP products in elution buffer from unknown N. meningitidis
samples, we can calculate the amount of the bacteria in unknown samples, and thus estimate the
seriousness of the infection.
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Figure 3.11: Calibration curve of nucleic acid concentrations of the LAMP products in elution
buffer versus the initial copy numbers of template DNA of N. meningitidis.
3.3.6 Limit of detection
By using a serial of 10-fold diluted N. meningitidis DNA samples, the LOD was studied.
The top left LAMP zones of the device were used for NC. All other LAMP zones were used for
N. meningitidis DNA detection. The initial template DNA copy numbers (before LAMP) ranged
from 3 × 106, 3 × 105, 3 × 104,… , to 3 × 10-2 per LAMP zone. After LAMP reactions, it was
observed from Figure 3.12a that even the initial template DNA was as low as 3 copies per LAMP
zone, the on-chip LAMP products still exhibited strong fluorescence. However, when the initial
template DNA was less than one copy, the fluorescence of the LAMP zones was as dim as the NC.
The cutoff gray value was determined to be 21.5, which was calculated as 3-fold standard
deviations of the mean gray value of the negative controls on the basis of the negative control. As
shown in Figure 3.12b, the gray value of the LAMP products from 3 copies of initial template
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DNA was much higher than that of cutoff line. This was further confirmed by gel electrophoresis
analysis of all LAMP products (Figure 3.12c). Therefore, the LOD of the microfluidic approach
was estimated to be ~3 DNA copies (or 7.4 fg) per LAMP zone, which is close to single-bacterium
detection sensitivity. This LOD was even 3 folds as low as that of conventional real-time PCR
method for N. meningitidis detection (9 copies/reaction).35
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Figure 3.12: LOD investigation. (a) Fluorescence images of LAMP products using a series of 10fold diluted N. meningitidis DNA samples ranging from (1)-(4): 3 × 102, 3 × 101, 3
× 100, 3 × 10-1 DNA copies per LAMP zone. (b) Gray values of the image of (a)-3
for LAMP products from 3 copies of template DNA. (c) Gel electrophoresis
analysis. Lanes 1-11: 100 bp marker, LAMP products from 3 × 106, 3 × 105, 3 ×
104, … , 3 × 100, 3 × 10-1, 3 × 10-2 copies of template DNA per LAMP zone,
respectively, and NC2.
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3.4

Summary
We have developed a versatile paper/PDMS hybrid microfluidic biochip for rapid and

sensitive detection of N. meningitidis. Due to the integration of LAMP on the biochip, the LOD of
~3 DNA copies per LAMP zone of N. meningitidis has been achieved within 45 minutes,
overcoming lengthy assay time and low-sensitivity issues in conventional methods for the
diagnosis of meningitis. This paper/PDMS hybrid microfluidic biochip incorporates the
advantages of high performance in liquid control from PDMS and of high porosity from paper for
storage and protection of LAMP primers.
The function of this hybrid microfluidic system is versatile. (1) The on-chip LAMP
detection based on calcein under a portable UV light pen doesn’t require any bulky specialized
equipment without the use of any centrifuges and cumbersome procedures for DNA isolation and
purification. The instrument-free detection makes the microfluidic system highly capable for the
diagnosis of meningitis in the field or in other resource-limited settings. (2) The design of the
microfluidic biochip allows on-chip LAMP products to be readily extracted for further
confirmatory tests (e.g. gel electrophoresis) and quantitative analysis based on the calibration
curve, as demonstrated in this work. This feature is suitable for the in-depth analysis and study of
patient samples in clinical laboratory settings.
Combining features (1) and (2), this paper/PDMS hybrid microfluidic biochip can provide
a comprehensive examination platform for patient samples to be tested in different settings. For
instance, after an initial yes/no qualitative assay of a patient sample in the field or resource-limited
settings, the sample tested by the biochip can be sent back to a clinical laboratory for further
confirmatory tests or quantitative analysis to examine the disease seriousness of the infection.
Moreover, by designing and changing different primers specific to other pathogens, this
paper/PDMS hybrid microfluidic biochip can have great potential in quick and early diagnosis of
a broad range of other infectious diseases, such as whooping cough, malaria, H1N1, and severe
acute respiratory syndrome (SARS), especially for developing countries. By scaling up channels
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and LAMP zones, our method can be used for higher-throughput screening of different infectious
diseases.
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Chapter 4: Pertussis Diagnosis on a POC Paper/PDMS Hybrid Biochip



The microfluidic approach was extended to rapid and sensitive pertussis diagnosis on the
low-cost paper/PDMS hybrid microfluidic biochip.



The LOD of 5 copies per LAMP zone for B. pertussis genomic DNA was achieved within
45 minutes.



The microfluidic approach was validated by testing 100 clinical nasopharyngeal samples.
The testing results exhibited high sensitivity and specificity, which were highly comparable
with the costly qPCR test.



The microfluidic approach provides great potential for POC pertussis diagnosis in a wide
variety of low-resource settings.
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4.1

Introduction
Pertussis, also known as whooping cough, is another example of infectious diseases that

frequently cause public health concerns. Pertussis caused by bacterium B. pertussis is a very
contagious and vaccine-preventable disease that remains endemic in the United States and
worldwide.11-12 In the United States, pertussis remains a common disease with frequent outbreaks.
For example, 48,277 cases of pertussis were reported in the most recent peak year of 2012.14
According to a report from the WHO in 2008, there were about 16 million pertussis cases
worldwide and about 195,000 deaths from these pertussis cases.13
Pertussis is commonly underdiagnosed because most cases present as mild or subclinical
infections.197-198 Pertussis presents with a runny nose, mild cough, nasal congestion, and low-grade
fever. Those syndromes caused by pertussis and the other respiratory infections such as
Respiratory Syncytial Virus (RSV), rhinovirus, Mycoplasma pneumoniae and Chlamydophila
pneumoniae are often indistinguishable, especially during the winter season.15 Only when a cough
becomes persistent or prominent do clinicians tend to suspect pertussis. Furthermore, patients
infected with pertussis sometimes may not present with any significant syndromes.199 Given that
pertussis is highly infectious during the acute phase (10 days) of infection, it is urgent to diagnose
and confirm suspected cases as soon as possible, and to limit contact with high-risk populations
such as infants and the elderly, who are more vulnerable to serious infections and complications
or death.200
The current technologies for pertussis diagnosis include bacterial culture, ELISA, and
qPCR. However, as mentioned in Section 1.1.3, these technologies have their owe limitations. For
example, bacterial culture takes several days or even weeks, and its detection sensitivity is low.23
ELISA is challenging to be used as an accurate method for pertussis diagnosis due to the low
sensitivity and specificity, and its procedures are complicated and laborious.34 qPCR is not specific
for pertussis diagnosis and requires expensive instruments in a well-equipped laboratory.39
As mentioned in Section 1.2.1, the microfluidic lab-on-a-chip technology offers a unique
opportunity for various biomedical applications and the development of POC testing devices to
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improve global health.76-77 Without relying on well-equipped laboratories, POC testing devices are
designed to perform testing in less hospitable sites such as on-site or in-field testing, which is
significant for immediate and convenient infectious disease diagnosis.
In Chapter 3, we developed a versatile paper/PDMS hybrid microfluidic biochip for N.
meningitidis detection. Herein, we extended the microfluidic approach to fast and accurate
pertussis diagnosis to demonstrate broad applications. The on-chip LAMP reaction and detection
of B. pertussis was successfully achieved within 1 hour. The LOD was as low as 5 copies per
LAMP zone, which showed the high detection sensitivity of the microfluidic approach for pertussis
diagnosis. By optimizing the centrifuge-free bacterial lysis protocol, we successfully achieved
direct detection of B. pertussis microorganisms in both artificial nasopharyngeal samples and real
human clinical samples. One hundred clinical samples were tested by using the microfluidic
approach and it was found that the testing results were highly comparable with the costly qPCR
test that relies on a well-equipped laboratory.
4.2

Experimental section

4.2.1 Chemicals and materials
Table 4.1 shows the LAMP primers for the target DNA sequences of the B. pertussis PT
promoter region.50
Table 4.1: LAMP primer sequences for PT promoter region of B. pertussis
Primer
FIP
BIP
F3
B3
FL
BL

Sequences (5’-3’)
TTGGATTGCAGTAGCGGGATGTGCATGCGTGCAGATTCGTC
CGCAAAGTCGCGCGATGGTAACGGATCACACCATGGCA
CCGCATACGTGTTGGCA
TGCGTTTTGATGGTGCCT
ACGGAAGAATCGAGGGTTTTGTAC
GTCACCGTCCGGACCGTG

All other chemicals and materials are listed in Section 2.1.
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No. of bases
41
38
17
18
24
18

4.2.2 Bacterial culture and DNA preparation
The bacterial culture and DNA preparation protocols for B. pertussis are described in
Section 2.2. The calculation of determining the copy numbers of the B. pertussis template DNA is
demonstrated in Section 2.5.
4.2.3 Microfluidic biochip design and fabrication
The design of the microfluidic biochip is shown in Figure 4.1, which was similar as
described in Section 3.2.3. The LAMP zones were used for NC, PC, and B. pertussis detection.
Fabrication of the microfluidic biochip was described in Section 2.3.1.

Figure 4.1: 3D schematic of the cross-section view of the paper/PDMS hybrid microfluidic
biochip for pertussis diagnosis.
4.2.4 On-chip LAMP procedures
The B. pertussis LAMP primers were pre-loaded in the LAMP zone for B. pertussis
detection; the PC DNA with its primer mix from the commercial LAMP kit was pre-loaded in the
PC LAMP zones (PC1); no primers was pre-loaded in the negative control LAMP zone (NC1).
Then, a 26 μL LAMP reaction mixture with the B. pertussis template DNA was introduced from
the inlet reservoir to fill the LAMP zones of the microfluidic biochip. In this way, the NC1 was in
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the presence of template DNA but not the primers. The PC1 used the PC DNA and its primer
mixture provided by the commercial LAMP kit.
In order to verify the NC1 and PC1 method, we used another type of negative control and
positive control in this study. All LAMP zones were pre-loaded with B. pertussis primers. Then, a
13 μL LMAP reaction mixture was prepared individually by adding the B. pertussis template DNA
sample (PC2), the testing sample, and the negative control sample (NC2), respectively. The
reaction mixture was introduced from each outlet reservoir to their corresponding LAMP zones of
the microfluidic biochip. In this way, the NC2 is in the presence of primers but not the template
DNA. The PC2 used the extracted B. pertussis template DNA and its primer mix.
After the samples with the LAMP reaction mixture were introduced into the biochip, the
inlet and outlets reservoirs were sealed with Epoxy glue to prevent the reagent evaporation during
LAMP reactions. Then the microfluidic biochip was heated by using a portable heater (see Section
3.2.4) at 63 °C for 45 minutes for LAMP reactions, followed by increasing the temperature to
95 °C for 2 minutes for the termination LAMP reactions.
The fluorescence indicator calcein-based detection principle is illustrated in Figure 3.1c.
As mentioned in Section 2.4, detection results after the LAMP reactions were imaged by a
smartphone camera (e.g. iPhone 5) under a portable UV light pen, and scanned by a Nikon Ti-E
fluorescence microscope (Melville, NY) using FITC optical filters (Ex = 495 nm; Em = 520 nm).
Gray values obtained by using software ImageJ and fluorescence intensities were used as digital
signals for further analysis of the smartphone camera captured images and the fluorescence
microscopy scanned images, respectively.
4.2.5 Confirmatory test
The detection results were further confirmed using the traditional gel electrophoresis
analysis (Sub-Cell GT, Bio-Rad, CA), as described in Section 2.6.
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4.2.6 Optimization of the lysis protocol of B. pertussis microorganisms
Artificial nasopharyngeal sample preparation: A tiny amount of bacterial colonies from B.
pertussis microorganism culture plate was swabbed and suspended in a 1 mL nasopharyngeal swab
prepared in a saline buffer to form an artificial nasopharyngeal sample to mimic a real clinical
sample. The artificial nasopharyngeal sample was adjusted to McFarland Standard 0.5 (Key
Scientific Products, TX) with an approximate bacterial density of 1.5 × 108 cfu/mL.180
Optimization of microorganism lysis: 3 µL of this artificial nasopharyngeal sample was
mixed with different amounts of the bacterial lysis buffer to generate a serial of artificial
sample/lysis buffer mixtures with ratios ranging from 1:0.5 to 1:5 (v/v). All those mixtures were
incubated at room temperature for 10 minutes to open the pathogenic microorganisms and release
their DNA. After that, those mixtures were purified and tested to obtain their nucleic acid
concentrations by using Nanodrop, as described in Section 2.5. In this way, the DNA amounts in
those mixtures were obtained to reflect the lysis performances of those mixtures at different ratios
between the artificial samples and the lysis buffers.
4.2.7 Direct detection of microorganisms in artificial nasopharyngeal samples
The instrument-free direct detection for B. pertussis microorganisms in the artificial
nasopharyngeal sample was performed based on the optimized microorganism lysis procedure.
Specifically, 3 μL of the artificial nasopharyngeal sample (B. pertussis microorganisms: ~1.5 ×
108 cfu/mL) was mixed with 3 μL bacterial lysis buffer and incubated at room temperature for
about 10 minutes. Then, 1 μL of the lysate with released DNA from B. pertussis microorganisms
in the artificial nasopharyngeal sample was directly used for the subsequent on-chip LAMP
reactions, as mentioned in Section 4.2.4.
4.2.8 Clinical sample test
One hundred clinical samples from pediatric patients were obtained from our collaborator,
Dr. Jennifer Dien Bard, at Children's Hospital Los Angeles. They were de-identified (no
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information about gender, age or ethnicity) remnant clinical nasopharyngeal swabs and aspirates,
which were collected and stored at -80 °C.
The clinical samples were directly tested based on the optimized microorganism lysis
procedures: 3 μL of the clinical samples was mixed with 3 μL bacterial lysis buffer, and incubated
at room temperature for about 10 minutes. Then 1 μL of the lysate was directly used for on-chip
LAMP reactions, as mentioned in Section 4.2.4.
4.3

Results and discussion

4.3.1 On-chip LAMP detection of B. pertussis using extracted DNA
We first tested the feasibility of the paper/PDMS hybrid microfluidic biochip for B.
pertussis detection by using extracted DNA. The LAMP primers specific to B. pertussis, and the
PC DNA with its primer mix from the commercial LAMP kit were respectively pre-loaded in their
corresponding LAMP zones in the hybrid microfluidic biochip. Calcein was used as a fluorescence
indicator. Before LAMP reactions, the fluorescence of calcein is quenched by manganese ions.
Then the byproduct pyrophosphate ions during LAMP reactions form complexes with manganese
ions. As a result, the free calcein combines magnesium ions and results in the emission of
fluorescence under UV light (see Figure 3.1c). Thus, visual confirmation of B. pertussis can be
achieved by an instrument-free method.
The cellphone camera captured fluorescence image in Figure 4.2a shows that the B.
pertussis sample and PC showed bright green fluorescence while NC1 only showed weak
background. The image was further processed by using the software ImageJ to obtain the gray
values. As shown in Figure 4.2c, a more than 3 folds difference between the B. pertussis/PC1 and
the NC1 was observed. The results were further confirmed by high-sensitivity fluorescence
microscopy. Similarly, strong fluorescence was observed in LAMP zones for B. pertussis and PC1,
but not for NC1 (Figure 4.2b). The fluorescence intensity of the B. pertussis LAMP products was
about 4.5 times higher than that of the NC1 (Figure 4.2d). Subsequently, we confirmed the results
by gel electrophoresis using the extracted LAMP products from different outlets, as shown in
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Figure 4.2e. The multiple ladder-pattern DNA bands from Lane 2 for B. pertussis confirmed the
success of the on-chip LAMP reaction.

Figure 4.2: On-chip LAMP detection of B. pertussis using extracted DNA by a portable UV light
pen (a) and fluorescence microscopy (b). (c) Gray values measured by ImageJ; (d)
Fluorescent intensities measured by a fluorescence microscope. (e) Gel
electrophoresis analysis. Lanes 1-3: 100 bp ladder, B. pertussis LAMP products,
NC1. The template DNA used was 5 × 106 copies per LAMP zone.
4.3.2 Specificity test
The identification of the exact B. pertussis bacteria is important to apply the accurate and
specific treatment and antibiotics for pertussis. B. parapertussis and B. holmesii are similar species
associated with respiratory infections in humans, which may also cause pertussis-like syndromes.
Therefore, the specificity of our approach for the detection of B. pertussis with its similar species
B. parapertussis and B. holmesii was explored.
For specificity test, all the LAMP zones were preloaded with B. pertussis primers. The
reaction mixtures with different DNA samples of B. pertussis, B. parapertussis, and B. holmesii
as well as the NC2 (without template DNA) were introduced from each outlet into their
corresponding LAMP zones separately. The results are shown in Figure 4.3a and 4.3b. It
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demonstrated that only the LAMP zones with B. pertussis DNA samples and its corresponding
LAMP primers exhibited strong fluorescence signals. In contrast, the LAMP zones with B.
parapertussis and B. holmesii DNA samples were observed to be similar as the NC2. The gel
electrophoresis test further confirmed the results. As shown in Figure 4.3c, only the LAMP
products extracted from the LAMP zones with B. pertussis DNA sample exhibited ladder-pattern
bands. The results indicated the high specificity of our approach for the detection of B. pertussis.

Figure 4.3: Specificity study. Fluorescence images for the specificity test among B. pertussis, B.
parapertussis (a) and B. holmesii (b). (c) Gel electrophoresis analysis. Lane 1: 100
bp marker; Lanes 2-3: products of B. pertussis and B. parapertussis from (a); Lanes
4-5: LAMP products of B. pertussis and B. holmesii from (b).
4.3.3 Limit of detection
By using a serial of 10-fold diluted B. pertussis DNA samples, the LOD was tested. The
initial copy number of the template DNA used was 5 × 105, 5 × 104, 5 × 103, 5 × 102, 5 × 101, 5 ×
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100, and 5 × 10-1 copies per LAMP zone. As shown in Figure 4.4a, the strong fluorescence of the
LAMP products was observed even when the initial template DNA was as low as 5 copies per
LAMP zone. However, when the initial template DNA was less than 5 copies, the fluorescence of
the LAMP products was as dim as the NC1. The cutoff gray value was calculated to be 35.5 on
the basis of 3-fold standard deviations of the mean gray value of the NC1, as shown in Figure 4.4b.
The gray values of the LAMP products from 5 copies of initial template DNA was much higher
than that of the cutoff. But the gray value of the LAMP products from less than 5 copies of initial
template DNA was below the cutoff gray value.
The result was further confirmed by gel electrophoresis (see Figure 4.4c). The ladderpattern bands of the LAMP products from 5 copies of initial DNA template of B. pertussis
indicated the success of the on-chip LAMP reactions. However, when the initial template DNA
was less than 5 copies, no DNA bands were observed. Therefore, we concluded that the LOD of
the on-chip LAMP approach for detection of B. pertussis was as low as ~5 copies per LAMP zone,
indicating high detection sensitivity for pertussis diagnosis.
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Figure 4.4: LOD investigation. (a) Fluorescence image of LAMP products using a series of 10fold diluted B. pertussis template DNA ranging from 50, 5 and 0.5 copies per
LAMP zone, as well as the NC. (b) Gray values of LAMP products. (c) Gel
electrophoresis analysis. Lanes 1-9: 100 bp marker, LAMP products from 5 × 105, 5
× 104, … , 5 × 100, 5 × 10-1 copies of the template DNA per LAMP zone, and NC1,
respectively.
4.3.4 Optimization of B. pertussis microorganism lysis
To avoid complicated and time-consuming sample preparation process such as DNA
extraction, we developed a simple centrifuge-free approach that was compatible to LAMP
reactions for direct detection of pathogenic microorganisms. This approach was successfully
applied to direct detection of N. meningitidis microorganisms in ACSF samples.177 In this work,
we further optimized the simple centrifuge-free microorganism lysis protocol by using a serial of
artificial sample/lysis buffer mixtures with different ratios from 1:0.5 to 1:5. Based on the obtained
DNA amounts from each artificial sample/lysis buffer mixture, the normalized microorganism
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lysis performances of these artificial sample/lysis buffer mixtures were demonstrated, as showed
in Figure 4.5. It demonstrated that high lysis performance could be achieved when the ratio
between the artificial sample and the bacterial lysis buffer was below 1.0. The lysis performance
in this ratio range (1:1 to 1:5) was 1.8 folds higher than that at the ratio of 1:0.5. However, smaller
ratios meant more bacterial lysis buffer needed, which could dilute the concentration of released
DNA from pathogenic microorganisms in samples. Therefore, the ratio of 1.0 between the sample
and the bacterial lysis buffer was chosen for the following test.

Figure 4.5: Optimization of the ratio between the artificial sample and the lysis buffer (v/v) based
on the normalized lysis performance of different mixtures.
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4.3.5 Instrument-free direct detection of B. pertussis microorganisms
We further performed the direct detection of B. pertussis microorganisms in artificial
nasopharyngeal samples based on the optimized microorganism lysis procedure. To eliminate the
false positives or false negatives, NC2 (without template DNA) and PC2 (using the extracted B.
pertussis template DNA, 1 μL ~7.5 × 104 copies/μL) were employed. All LAMP zones were preloaded with B. pertussis primers, then the extracted B. pertussis DNA sample, the lysed artificial
sample (an artificial nasopharyngeal sample/bacterial lysis buffer mixture after incubation), and
the NC2 with their LMAP reaction mixture were introduced from each outlet to their
corresponding LAMP zones. Assuming the microorganism lysis was thoroughly completed, the
initial template DNA amount from both the extracted B. pertussis and the lysed artificial sample
were the same (~7.5 × 104 copies).
Figure 4.6 shows the results of the instrument-free direct detection of the artificial
nasopharyngeal sample. It can be seen that strong fluorescence could be produced by using the
artificial nasopharyngeal sample as using the extracted DNA sample (Figure 4.6a and 4.6b), which
was much higher than that from the NC2. However, no obvious differences were observed by
comparing the gray values and fluorescence intensities of the LAMP products from both the
artificial nasopharyngeal sample and the extracted DNA sample (Figure 4.6c and Figure 4.6d).
The results were further confirmed by the gel electrophoresis analysis. As shown in Figure 4.6e,
the LAMP products from both the artificial nasopharyngeal sample and the extracted B. pertussis
DNA sample showed clear ladder-pattern DNA ladders. The successful direct detection of the
artificial nasopharyngeal sample indicated that our simple optimized microorganism lysis
approach was very efficient and totally compatible to on-chip LAMP reactions and detections
without any inhibition problems. Therefore, it laid a good foundation for direct detection of clinic
samples by using the approach that we developed without relying on any equipment (e.g.
centrifuge, water bath) or any complicated and time-consuming sample preparation process (e.g.
DNA extraction).
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Figure 4.6: Instrument-free detection of B. pertussis microorganisms. Fluorescence images of the
on-chip LAMP detection under a portable UV light pen (a) and a fluorescence
microscopy (b). Gray values (c) and fluorescent intensities (d) of the LAMP
products from the ACSF sample. (e) Gel electrophoresis analysis. Lanes 1-4: 100
bp marker; LAMP products from the artificial nasopharyngeal sample and the
extracted B. pertussis DNA sample respectively; NC2.
4.3.6 Clinical sample detection
To validate the paper/PDMS hybrid microfluidic biochip for pertussis diagnosis, 100
clinical samples were directly tested by using the optimized centrifuge-free microorganism lysis
protocol. NC2 (without template DNA) was used in each run. All remnant clinical samples were
tested to be either positive or negative for B. pertussis by using a validated qPCR assay from
Children's Hospital Los Angeles. The remnant de-identified clinical samples fit our research aim
of determining and validating the on-chip LAMP molecular diagnostic method without bias.
The sensitivity and specificity were calculated by using qPCR as a reference assay. We
compared our testing results with the qPCR testing results (Table 4.2). Bacterial culture was not
performed on the clinical samples since culture was a suboptimal testing method compared to
molecular detection for the diagnosis of pertussis. As shown in Table 4.2, by comparing the qPCR
testing results to our microfluidic LAMP test, we found that all the 53 samples that were tested to
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be positive by qPCR were tested to be positive as well by our method. In those 53 samples, one
sample was initially tested to be negative according to the qPCR method while it was tested to be
positive according to our method. Then this sample was retested by using the qPCR method and
was finally confirmed to be positive, proving our testing result was correct. For the 47 negatives
from the qPCR test, however, our testing results found 45 of them were negatives and 2 of them
were positives. LAMP has been reported as a more sensitive assay than qPCR by producing higher
amount of amplicons (>103 folds).201-204 Thus, the 2 conflicting testing results might be two weak
positives. Because our on-chip LAMP test is more sensitive than the qPCR test, qPCR was not
able to detect trace amount of pathogen.
Table 4.2: Results of clinical samples from the microfluidic LAMP test and the qPCR test*
qPCR (+)

qPCR (-)

On-chip LAMP (+)

53

2

On-chip LAMP (-)

0

45

No. of clinical
samples

Sensitivity
(%)

100

100

Specificity
Overall
(%)
agreement (%)
96

98

* assuming qPCR results are correct
To determine the accuracy of our test, sensitivity and specificity were calculated by using
qPCR

as

the

reference

𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 + 𝑓𝑎𝑙𝑠𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠

correctly

identified,

𝑓𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 + 𝑡𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠

identified,

𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑟𝑒𝑠𝑢𝑙𝑡𝑠

4.2).

Sensitivity

was

calculated

as

was

100%.

Specificity

was

calculated

as

× 100% to measure the proportion of actual negatives that are

which

𝑡ℎ𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑐𝑡 𝑟𝑒𝑠𝑢𝑙𝑡𝑠

(Table

× 100% to measure the proportion of actual positives that are

which

𝑡𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠

correctly

method

was

96%.

Overall

agreement

was

calculated

as

× 100%, which was 98%. In terms of specificity and sensitivity, the

results indicated that our test has a high accuracy and is highly comparable to the costly qPCR test
that has to be conducted in a well-equipped laboratory.
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4.4

Summary
The low-cost paper/PDMS hybrid microfluidic biochip integrated with LAMP was

successfully extended for rapid and accurate diagnosis of pertussis. The biochip was further
validated by clinical samples.
This microfluidic approach for pertussis diagnosis has five significant features. (1) It is
low-cost. The ready-to-use paper/PDMS hybrid microfluidic biochip costs only a few cents. (2)
The microfluidic approach is instrument-free. No specialized equipment in laboratories such as a
thermal cycler or a centrifuge is required. Due to the simple centrifuge-free microorganism lysis
approach, clinical samples can be directly used for testing without any complicated sample
preparation process such as DNA extraction. The testing results are detectable by the naked eye.
(3) It provides a highly sensitive and specific diagnostic approach. The LOD is as low as 5 copies
per LAMP zone for B. pertussis detection. High specific detection for B. pertussis with other
similar Bordetella species has been achieved. (4) The method is fast. The whole assay procedures
take less than 1 hour. (5) The sensitivity and specificity by testing 100 human clinical samples
show the high accuracy of our microfluidic diagnostic approach, which is quite comparable to the
costly qPCR test that requires well-equipped laboratories.
This paper/PDMS hybrid microfluidic biochip integrated with LAMP provides a POC
testing platform for fast and accurate pertussis diagnosis for resource-limited settings such as
physician's offices, schools, and developing nations. In addition, this microfluidic diagnostic
approach should have broad applications in POC testing of a variety of other pathogens (e.g. Zika
virus).
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Chapter 5: A Paper/PDMS Hybrid Biochip for Multiplexed Pathogen
Detection

Reproduced in part with permission from the Elsevier.


Parts of this chapter were published in Biosensors and Bioelectronics as a research article
in 2016. (M Dou, ST Sanjay, DC Dominguez, P Liu, F Xu, XJ Li. Biosensors and
Bioelectronics, 2017, 87, 865-873.)



A low-cost paper/PDMS hybrid microfluidic biochip integrated with parallel LAMP
reactions has been developed for instrument-free multiplexed detection.



This work for the first time provides a microfluidic approach for simultaneous detection of
three most common meningitis-causing pathogens, N. meningitidis, S. pneumoniae and
Hib.
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5.1

Introduction
Although great progress has been made to prevent infectious diseases, multiple infectious

diseases such as meningitis still cause thousands of deaths every year globally. As mentioned in
Section 1.1.1, meningitis is an inflammation of the lining surrounding the spine and the brain,
which can become fatal in as early as 24 hours after symptoms occur. Meningitis can be caused by
infection with bacteria, viruses, and fungi. Bacterial meningitis remains the most serious form of
this disease.4
N. meningitidis, S. pneumoniae and Hib are three major pathogens causing bacterial
meningitis. As a medical emergency, the immediate antibiotic therapy is imperative for bacterial
meningitis, which must not be postponed by diagnostic delays.7 In addition, identification of the
exact bacteria causing the disease is vital because treatment and antibiotics differ for each type.
Due to the high fatality rate and the serious damaging effect caused by untreated meningitis
especially in rural high-poverty areas, a simple, low-cost, rapid and highly sensitive approach for
immediate multiplexed bacterial meningitis diagnosis is in great need.
As mentioned in Section 1.1.3, bacterial culture and gram staining are key approaches to
the laboratory diagnosis of bacterial meningitis.18 However, their limitations are obvious. (1) Their
detection sensitivity is low. (2) Their detection rates decrease for patients receiving antibiotic pretreatment. (3) They have to be done in laboratories by well-trained personnel. (4) Bacterial culture
may take more than 72 hours for identification.19 Recently, molecular diagnostic methods such as
qPCR and LAMP have been increasingly used to provide rapid detection of bacterial meningitis
with higher sensitivity and specificity.35-36 qPCR has become a valuable technique for the detection
of bacterial meningitis pathogens,35 but it is costly. There have been several reports on rapid
diagnosis of bacterial meningitis (e.g., N. meningitidis, S. pneumoniae, and Hib) by using
conventional off-chip LAMP.45-49 However, none of these LAMP methods achieved multiplexed
bacterial meningitis detection. In addition, specialized equipment is required in laboratories for
these DNA amplification-based methods, such as qPCR (e.g., ~$60000), thermal cyclers,
centrifuges, and fluorescent microscopes, making them not applicable in low-resource settings.
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With various advantages including low sample/reagent consumption, integration,
miniaturization and automation, the microfluidic lab-on-a-chip provides a platform for a variety
of human health diagnostics with high efficiency,61, 65-68, 70-74, 205-206 as well as the possibility for
multiplexed detection (see Section 1.2.1).116, 125, 207 By taking advantage of different substrates, the
Li group previously developed a paper/PDMS hybrid microfluidic device integrated with aptamerfunctionalized GO nanosensors for one-step detection of multiple foodborne pathogens
simultaneously,116 as described in Section 1.2.3. However, the detection sensitivity is not
comparable to DNA amplification-based assays. DNA amplification is usually essential for DNAbased techniques to achieve high detection sensitivity. Therefore, we developed another hybrid
microfluidic device integrated with LAMP for sensitive infectious disease diagnosis,177 as
demonstrated in Chapter 3. Although high sensitivity was exhibited, only one pathogen was
measured from each assay and pathogen lysis steps were not integrated on the chip. In addition,
other microfluidic device-based LAMP methods have been reported for the detection of different
pathogens.125-133, 143, 177 However, as discussed in Section 1.3.1, certain limitations hindered their
wide applications for low-resource settings, including dependence on bulky detection systems,127,
143

supporting equipment,128 and complicated sample preparation steps.127
The multiplexed pathogen detection can provide richer information, higher throughput,

more convenience, and less sample consumption and less detrimental effects on patients during
sampling, compared to multiple times of repeated singleplexed assays. Although LAMP has
received increasing attention for applications in low-resource settings, the multiplexed LAMP
detection is challenging because of complexities from multiple primer sets and complicated ladderpatterned amplicons.51-53 Most conventional LAMP methods by just mixing different primers for
multiple pathogens in a single tube for simultaneous pathogen detection can only identify the
occurrence of amplification reactions, but are not efficient to identify the specific target
pathogens.54-55 Possibly due to this reason, no LAMP methods were reported for multiplexed
meningitis diagnosis yet.
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Herein, by taking advantage of ease of multiple-compartment fabrication in microfluidics
for parallel LAMP reactions, we developed a paper/PDMS hybrid microfluidic biochip for
simultaneous LAMP detection of three most common meningitis-causing pathogens with high
sensitivity and specificity, N. meningitidis, S. pneumoniae and Hib.208 Three types of pathogenic
microorganisms spiked in ACSF samples were directly analyzed, and detection results were
observable to the naked eye within 1 hour, without using laborious sample preparation procedures
or any specialized equipment during the entire assay. The LODs of a few DNA copies per LAMP
zone were achieved.
5.2

Experimental section

5.2.1 Chemicals and materials
Table 5.1 shows the primers which were purchased from Integrated DNA Technologies
(Coralville, IA) for the target DNA sequences of the N. meningitidis ctrA gene, the S. pneumoniae
lytA gene, and the Hib capsulation locus region II.46-47, 49
Table 5.1: LAMP primer sequences for N. meningitidis, S. pneumoniae, and Hib, respectively
Primer
FIP
BIP
F3
B3
FL
BL
Primer
FIP
BIP
F3
B3
BL
Primer
FIP
BIP
F3
B3
FL

N. meningitidis LAMP primer sequences
Sequences (5’-3’)
No. of bases
CAAACACACCACGCGCATCAGATCTGAAGCCATTGGCCGTA
41
TGTTCCGCTATACGCCATTGGTACTGCCATAACCTTGAGCAA
42
AGC(C/T)AGAGGCTTATCGCTT
19
ATACCGTTGGAATCTCTGCC
20
CGATCTTGCAAACCGCCC
18
GCAGAACGTCAGGATAAATGGA
22
S. pneumoniae LAMP primer sequences
Sequences (5’-3’)
No. of bases
CCGCCAGTGATAATCCGCTTCACACTCAACTGGGAATCCGC
41
TCTCGCACATTGTTGGGAACGGCCAGGCACCATTATCAACAGG
43
GCGTGCAACCATATAGGCAA
20
AGCATTCCAACCGCC
15
TGCATCATGCAGGTAGGA
18
Hib LAMP primer sequences
Sequences (5’-3’)
No. of bases
ACTTCTTTACCAAAGGCATCATTTTGCGTTTGTTGACGCCAAATTCTGG
49
CTGATGATATGGGTACATCTGTTCGCGAAGAATGAGAAGTTTTGTGG
47
CGCCAATACATTCAACAAGA
20
CGTATGGGGTTTGTGCA
17
GCAGACGACCAAAGGTATCTTG
22
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All other chemicals and materials are listed in Section 2.1.
5.2.2 Bacterial culture and DNA preparation
The bacterial culture and DNA preparation protocols for N. meningitidis, S. pneumoniae,
and Hib are described in Section 2.2. The calculation of determining the copy numbers of the N.
meningitidis, S. pneumoniae, and Hib template DNA is demonstrated in Section 2.5.
5.2.3 Microfluidic biochip design and fabrication
The microfluidic biochip consists of three layers, as shown in Figure 5.1a. The top layer is
a PDMS layer including a central inlet reservoir with a diameter of 1.0 mm, and 4 microchannels
(100 µm in width and depth) for reagent delivery. The middle layer is also a PDMS layer
containing 8 LAMP zones (diameter 2.0 mm, and depth 1.0 mm) for LAMP reactions and
detection, 4 outlet reservoirs with a diameter of 1.0 mm, and 4 microchannels at the bottom surface
of the middle layer. Different LAMP zones were designated for different pathogen detection (N.
meningitidis, S. pneumoniae, and Hib, respectively) and negative control (NC). A Whatman #1
chromatography paper disk (diameter 2.0 mm) was placed inside each LAMP zone. The bottom
layer is a glass slide for structure support. Figure 5.1b is a photograph of the assembled biochip on
a fluorescence microscope stage.
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Figure 5.1: Layout of the paper/PDMS hybrid microfluidic biochip for multiplexed pathogen
detection. (a) 3D illustration. (b) A photograph of the biochip.
Specific DNA primers for N. meningitidis, S. pneumoniae and Hib DNA sequences were
pre-loaded on paper disks in LAMP zones. No primers were pre-loaded in LAMP zones for the
negative control (NC1) for the convenience of subsequent reagent delivery, which was confirmed
to provide consistent results with another type of negative control (NC2) in the presence of primers
but not the template DNA (see Figure 5.6 for more information).
Fabrication of the microfluidic biochip was described in Section 2.3.1.
5.2.4 On-chip LAMP procedures
A 26 μL LAMP mixture was prepared and introduced into the LMAP zones of the biochip
from the inlet. The inlet and outlets were sealed with Epoxy glue afterward. The microfluidic
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biochip was heated by using the portable heater (see Section 3.2.4) at 63 °C for 1 hour for LAMP
reactions and was further heated at 95 °C for 2 minutes to terminate the LAMP reactions.
The detection principle of the LAMP zone is illustrated in Figure 3.1c. After LAMP
reactions, as described in Section 2.4.1, a cellphone camera (e.g., iPhone 5) was used to capture
the generated fluorescence images under a portable UV light pen. The cellphone camera captured
images were analyzed by the NIH software ImageJ to obtain gray values. The fluorescence
intensities were further measured by using the Nikon Ti-E fluorescence microscope (Melville, NY)
equipped with an appropriate FITC optical filters to confirm instrument-free detection results, as
described in Section 2.4.2.
5.2.5 Confirmatory test
LAMP products were analyzed using the conventional gel electrophoresis for a
confirmatory test, as described in Section 2.6.
5.2.6 Multiplexed detection of microorganisms
The ACSF buffer preparation process is described in Section 3.2.6.
Microorganisms were spiked in ACSF to prepare mock clinical samples. We swabbed a
tiny amount of bacterial colonies from each microorganism culture plate of N. meningitidis, S.
pneumoniae and Hib, and suspended them with 1 mL ACSF buffer to form an ACSF sample for
bacterial cell lysis by adjusting the turbidity to McFarland Standard 0.5 (Key Scientific Products,
TX) with an approximate bacterial density of 1.5 × 108 cfu/mL.180
On-chip lysis was integrated on the chip. To test microorganism in ACSF samples, only 2
μL of the ACSF sample was mixed with 18 μL of the bacterial lysis buffer (50 mM Tris buffer
(pH 7.5), 4 M urea and 0.1% triton) to prepare the bacterial lysis buffer/ACSF sample mixture.
Then 16 μL of this mixture was introduced into the microfluidic biochip from the common inlet.
The on-chip lysis step could be simply completed by just incubating the lysis buffer/ACSF sample
mixture in the microfluidic biochip for about 10 minutes at room temperature. After the lysis
buffer/ACSF sample mixture dried to avoid dilution of LAMP solutions, the LAMP reaction
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mixture was introduced into the microfluidic biochip to complete the subsequent LAMP reactions
for multiplexed detection of meningitis microorganisms from ACSF samples. The bacterial cell
lysis and incubation process could also be performed off the chip, with no difference in LAMP
results when compared with on-chip lysis procedures (see Figure 5.6 for more information). If
lysis incubation was performed off-chip, 2 μL of the lysate was directly used to prepare the LAMP
mixture.
5.3

Results and discussion

5.3.1 Detection of individual pathogen by using extracted DNA
By using the template DNA extracted from bacterial culture, we first tested the feasibility
of the on-chip LAMP detection of each pathogen separately.
The paper is a highly porous material with 3D structures and a high surface-to-volume
ratio.181 It is believed that paper is able to protect DNA in harsh conditions, so the paper has been
advantageously used in collecting, storing and processing DNA samples.183, 209-210 Therefore, in
this work, we placed a paper disk in each of the LAMP zones, forming a paper/PDMS hybrid
microfluidic biochip. In this way, paper functions as a 3D substrate where DNA primers were preloaded for subsequent on-chip LAMP reactions. Previously, the Li group also developed a few
other paper/polymer hybrid microfluidic devices for rapid disease diagnosis.116, 211 As discussed
in Section 1.2.3, hybrid microfluidic devices can draw more benefits from multiple device
substrates.66-67
Before LAMP reactions, the fluorescence of calcein, the detection reagent, is quenched by
manganese ions. After LAMP reactions, the byproduct pyrophosphate ion forms a complex with
the manganese ion. As a result, calcein is free to combine magnesium ions, producing bright
fluorescence (see Figure 3.1c). Hence, the instrument-free determination can be achieved by the
naked eye or a smartphone camera, based on fluorescence from the LAMP zones under a UV light
pen. Figure 5.2b and 5.2c shows photographs taken by a smartphone camera for the on-chip LAMP
pathogen detection of S. pneumoniae and Hib using extracted DNA under a portable UV light pen.
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Only the LAMP zones for S. pneumoniae and Hib detection were lit up with bright green
fluorescence but not for NC1. Similar results was obtained by fluorescence microscopy (Figure
5.2e and 5.2f) to confirm the results from a smartphone camera. Similarly, the on-chip LAMP
pathogen detection of N. meningitidis was performed by using a smartphone camera and a
fluorescence microscope, respectively. As shown in Figure 5.2a and Figure 5.2d, LAMP zones for
N. meningitidis detection exhibited strong fluorescence, while very weak fluorescence was
exhibited for NC1.
In addition, the hybrid microfluidic biochip was designed to offer versatile functions.
Different LAMP products can be extracted separately from each outlet for confirmatory tests such
as by gel electrophoresis. As can be seen from Figure 5.2g, the specific ladder-pattern bands of
LAMP products from each pathogen but not from NC1 represented a mixture of DNA amplicons
with different sizes due to loop-mediated reactions, which confirmed that the on-chip LAMP
reactions for singleplexed pathogen detection were successful. As also can be seen from Figure
5.2g, the complicated ladder-patter bands make it challenging for multiplexed LAMP detection in
a single microwell or tube.
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Figure 5.2: On-chip LAMP detection of N. meningitidis, S. pneumoniae, and Hib individually
using extracted DNA by a smartphone camera (a-c) and fluorescence microscopy
(d-f). (g) Gel electrophoresis analysis. Lanes N.M., S.P., H.I. were LAMP products
from N. meningitidis, S. pneumoniae, and Hib respectively; Lane M, 100 bp
ladders; Lane NC, negative control. The extracted template DNA of N.
meningitidis, S. pneumoniae and Hib used were 3 × 106, 6 × 106 and 5 × 106 copies
per LAMP zone, respectively.
5.3.2 Multiplexed meningitis detection by using extracted DNA
Multiple pathogens sometimes can coexist. Multiplexed pathogen detection provides a
more efficient way for rapid diagnostics from the real world through a single assay, avoiding
inconvenience and delays from multiple repeated singleplexed assays. Therefore, upon the success
of the singleplexed detection, we investigated the feasibility of our approach for multiplexed
detection of three meningitis-causing pathogens (i.e. N. meningitidis, S. pneumoniae and Hib)
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using their extracted DNA. Different primers targeting different pathogens were preloaded in
different LAMP zones in the ready-to-use biochip. During the multiplexed assay, a LAMP reaction
mixture including template DNA from all the three pathogens was introduced from the common
inlet. The LAMP zones in the middle PDMS layer were not directly connected on the same plane,
which could effectively prevent the cross-talk and the risk of cross-contamination among these
different LAMP zones. This allowed us to perform parallel LAMP reactions in independent
compartments for multiplexed bacterial meningitis diagnosis.
As shown in Figure 5.3a, end point detection results could be visually determined from the
green fluorescence of the LAMP zones under a portable UV light. All the LAMP zones targeting
these three pathogens were lit up with strong fluorescence, but not for NC1 LAMP zones. Their
average gray values were measured by the ImageJ software (Figure 5.3c), quantitatively indicating
the brightness difference between pathogen detection zones and NC1 zones. In addition, the
fluorescence image and intensities from Figure 5.3b and 5.3d show similar results. Fluorescence
intensities of the LAMP products from the three pathogens were about 5 times higher than that of
the NC1. Furthermore, LAMP products from these three pathogens were separately collected from
each outlet to run gel electrophoresis. Figure 5.3e shows that the ladder-pattern bands of LAMP
products from these three pathogens further verified the success of multiplexed on-chip meningitis
detection.
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Figure 5.3: On-chip LAMP multiplexed detection of N. meningitidis (N.M.), S. pneumoniae
(S.P.) and Hib (H.I.) using extracted DNA by a smartphone camera (a) and
fluorescence microscopy (b). (c) Gray values. (d) Fluorescent intensities. (e) Gel
electrophoresis analysis. Lanes 1-5: 100 bp ladder, LAMP products from N.
meningitidis, S. pneumoniae, and Hib, and NC1.
5.3.3 Specificity test
Identification of the exact bacteria causing meningitis is vital because treatment and
antibiotics differ for each type. To investigate the specificity of the approach for N. meningitidis,
S. pneumoniae and Hib detection, we designed a microfluidic array by testing these three
pathogens with their corresponding and non-corresponding LAMP primers separately (Figure
5.4a).
As shown in Figure 5.4a, specific LAMP primers for N. meningitidis, S. pneumoniae, and
Hib were pre-loaded in lateral rows from the top to the bottom, respectively. Blank and three DNA
samples of N. meningitidis, S. pneumoniae and Hib were introduced to columns from left to right,
respectively. It can be seen from Figure 5.4b that only LAMP zones with corresponding primers
and DNA samples showed bright green fluorescence. For instance, for the column with the N.
meningitidis DNA sample, only the LAMP zone with pre-loaded N. meningitidis LAMP primers
produced bright fluorescence, the intensity of which was about 5 times higher than that of the blank
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(Figure 5.4c). Other LAMP zones were as dim as the blank. Similarly, phenomena were observed
with S. pneumoniae and Hib, indicating the high specificity of the approach for multiplexed
meningitis detection.

Figure 5.4: Specificity test among N. meningitidis, S. pneumoniae and Hib with their
corresponding and non-corresponding LAMP primers using a microfluidic array (a)
by a fluorescence image (b) and fluorescence intensities (c). Lateral rows from the
top to the bottom were pre-loaded with LAMP primers for N. meningitidis (N.M.),
S. pneumoniae (S.P.) and Hib (H.I.) respectively; columns from left to right were
introduced with Blank, DNA samples of N. meningitidis (N.M.), S. pneumoniae
(S.P.) and Hib (H.I.), respectively.
5.3.4 Instrument-free detection of multiple pathogenic microorganisms
The multiplexed bacterial meningitis detection discussed above was performed by using
extracted template DNA. However, to test real clinical samples, such as CSF or blood, extra
complicated sample preparing steps including DNA isolation/purification before the amplification
are required. Traditional clinical sample preparations not only are time-consuming but also rely on
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specialized equipment such as a centrifuge in laboratory settings. These limitations make them not
applicable for POC pathogen detection.
In this work, we integrated the simple centrifuge-free microorganism lysis procedures for
instrument-free detection of multiple bacterial meningitis causing microorganisms (i.e. N.
meningitidis, S. pneumoniae and Hib) in ACSF samples. The mixture of the ACSF sample with
the bacterial lysis buffer was simply introduced into the biochip from the common inlet and was
further incubated for about 10 minutes at room temperature to complete the lysis step before the
introduction of the LAMP reaction mixture. This on-chip lysis procedure was not only simple,
without the use of any centrifuges, but also fully compatible with the subsequent LAMP reaction.
No noticeable inhibition to LAMP was observed. As shown in Figure 5.5a and 5.5b, LAMP
products from the ACSF sample produced bright fluorescence under a portable UV light pen or a
fluorescence microscope. The fluorescence difference between pathogen LAMP zones and NC1
zones can be readily distinguishable by the naked eye, as indicated in the photograph taken by a
smartphone camera (Figure 5.5a). Their gray values and fluorescence intensities shown in Figure
5.5c and 5.5d can indicate their difference quantitatively. In addition, as shown in Figure 5.5e, the
ladder-pattern bands from the gel electrophoresis analysis of the LMAP products from these three
pathogens further confirmed the success of the instrument-free multiplexed detection of
microorganisms. No significant difference was observed between using the ACSF sample (Figure
5.5) and using the extracted DNA (Figure 5.3). Therefore, the direct multiplexed detection of
pathogenic microorganisms was readily achieved without relying on any special equipment.
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Figure 5.5: Multiplexed detection of pathogenic microorganisms of N. meningitidis (N.M.), S.
pneumoniae (S.P.) and Hib (H.I.) in an ACSF sample by a smartphone camera (a)
and fluorescence microscopy (b). (c) Gray values. (d) Fluorescent intensities. (e)
Gel electrophoresis analysis. Lanes 1-5: 100 bp ladder, LAMP products of N.
meningitidis, S. pneumoniae, and Hib, and NC1.
By performing microorganism lysis and incubation process off-chip, and using NC2 in the
presence of primers but not the ACSF microorganism sample (template DNA), we further
investigated the performance of the multiplexed detection of microorganisms in ACSF samples.
Two microliters of the lysate prepared off-chip were directly used to prepare the LAMP reaction
mixture which was then introduced from each outlet to fill the LAMP zones for the subsequent
LAMP reaction. This NC2 in the presence of primers but not the ACSF microorganism sample
(template DNA) with the off-chip lysis procedure (Figure 5.6) confirmed consistent results from
the other type of NC1 in the presence of template DNA but not the primers with the on-chip lysis
procedure (see Figure 5.5).
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Figure 5.6: A fluorescence image of multiplexed LAMP products by using microorganisms of N.
meningitidis (N.M.), S. pneumoniae (S.P.) and Hib (H.I.) spiked in an ACSF
sample. The microorganism lysis and incubation process were performed off chip.
Two microliters of the lysate were directly used to prepare the LAMP reaction
mixture and the LAMP reaction mixture was then introduced from each outlet to fill
the LAMP zones. This NC2 in the presence of primers but not the ACSF
microorganism sample (template DNA) confirmed consistent results from the other
type of NC1 in the presence of template DNA but not the primers which were
mostly used in our tests for the convenience of reagent and sample delivery.
5.3.5 Limits of detection
By using a serial of 10-fold diluted template DNA samples, the LOD for each pathogen
was tested.
The fluorescence images in Figure 5.7a indicate that strong fluorescence was still observed
even when the initial template DNA was only a few copies per LAMP zone. On the contrary, no
obvious fluorescence was generated when the template DNA was lower than 3 copies per LAMP
zone. The gray values and fluorescence intensities of different LAMP zones for N. meningitidis,
S. pneumoniae, and Hib are shown in Figure 5.7b and 5.7c, respectively. On the basis of 3-fold
standard deviations of the mean gray value of the negative controls, the cutoff gray values for N.
meningitidis, S. pneumoniae, and Hib were calculated to be 48.1, 41.3 and 42.5 respectively, as
shown by the dashed lines in Figure 5.7b. The gray values of the LAMP products from 3 copies
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of initial DNA template of N. meningitidis, 6 copies of initial DNA template of S. pneumoniae and
5 copies of initial DNA template of Hib were much higher than the cutoff lines. Similar results
were achieved by measuring the fluorescence intensities (Figure 5.7c).
Gel electrophoresis analysis results from Figure 5.7d further confirmed the results. The
ladder-pattern bands of the LAMP products from 3 copies of initial DNA template of N.
meningitidis, 6 copies of initial DNA template of S. pneumoniae and 5 copies of initial DNA
template of Hib indicated the success of the on-chip LAMP reactions. However, when the initial
template DNA was less than one copy, no DNA bands were observed. Therefore, we concluded
that the LODs of N. meningitidis, S. pneumoniae, and Hib were 3 copies, 6 copies and 5 copies per
LAMP zone, respectively. This indicates that although no expensive instrument was used, the
sensitivity of our microfluidic method is comparable to or higher than qPCR (9 copies for N.
meningitidis,35,212 14 copies of S. pneumoniae,213 and 10 copies for Hib per reaction37).
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Figure 5.7: LOD investigation. Fluorescence images (a), gray values (b) and fluorescence
intensities (c) of LAMP products from N. meningitidis (N.M.), S. pneumoniae (S.P.)
and Hib (H.I.) using a serial of 10-fold diluted template DNA samples. (c) Gel
electrophoresis analysis. Lane 1: 100 bp marker; Lanes 2-8: LAMP products using a
series of 10-fold diluted DNA samples of (1) N. meningitidis 3 × 105, 3 × 104, …, 3
× 100, 3 × 10-1 copies per LAMP zone; (2) S. pneumoniae 6 × 105, 6 × 104, …, 6 ×
100, 6 × 10-1 copies per LAMP zone; (3) Hib 5 × 105, 5 × 104, …, 5 × 100, 5 × 10-1
copies per LAMP zone; Lane 9: NC1;
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5.4

Summary
We have developed a low-cost paper/PDMS hybrid microfluidic biochip for multiplexed

instrument-free detection of three major meningitis-causing pathogens, N. meningitidis, S.
pneumoniae and Hib. Microorganisms in ACSF samples can be directly analyzed thank to the
integration of simple centrifuge-free lysis on the chip, thus avoiding cumbersome sample
preparation procedures in conventional pathogen methods. The visual detection can be readily
achieved by the naked eye within one hour based on the recovered fluorescence under a portable
UV light, without relying on any specialized instruments. The LOD of our approach for N.
meningitidis, S. pneumoniae, and Hib are 3 copies, 6 copies and 5 copies per LAMP zone,
comparable to those of real-time PCR. The paper/PDMS hybrid microfluidic biochip uses the
merits of different low-cost materials, such as high liquid manipulation performance and
transparency from PDMS and 3D porous structures for preserving DNA primers from cellulose
paper.
With all of these characteristics, the hybrid microfluidic biochip is able to achieve POC
detection of multiplexed meningitis, especially in resource-limited settings. In addition, by
employing other DNA primers targeting to different pathogens, this hybrid microfluidic biochip
should have broad applications in instrument-free multiplexed detection of a variety of other
pathogens (e.g. foodborne pathogens).
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Chapter 6: A Paper/PMMA Hybrid SpinChip for mLAMP Detection



A paper/PMMA hybrid CD-like microfluidic SpinChip integrated with ssDNA probefunctionalized GO nanosensors has been developed for multiplex LAMP (mLAMP)
detection.



This work for the first time provides a simple and effective microfluidic approach for
quantitative mLAMP detection.



Paper in this hybrid SpinChip facilitates the integration of probe-functionalized
nanosensors without any complicated surface modifications.
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6.1

Introduction
LAMP is a relatively new nucleic acid amplification technique, which is simple, rapid,

specific, sensitive and cost-effective (see Section 1.1.3).44 Since LAMP is an isothermal nucleic
acid amplification technique, this eradicates the need for expensive thermocyclers required by
PCR, making LAMP have great potential for pathogen detection in low resource settings.44
However, the application of LAMP is often restricted by the lack of simple and robust methods
for multiplex LAMP (mLAMP). Multiplex LAMP can amplify several DNA targets in one
reaction and be employed for simultaneous detection of multiple pathogens, which can provide
richer information and more conveniences to end users, consume fewer samples and reagents, and
reduce the detrimental effect for patients caused by sampling. The mLAMP detection is
challenging mainly due to complexities from multiple primer sets and complicated ladder-pattered
LAMP products from loop-mediated reactions. There are only a few reports on mLAMP detection,
in which several different primer sets and other reaction reagents are mixed in a single tube.51-53
However, the subsequent gel electrophoresis assisted detection method is not effective because of
the complicated ladder-pattern bands of LAMP products from different targets (e.g., see Figure
6.4). As a result, the traditional tube-based mLAMP can only identify the occurrence of
amplifications but cannot effectively identify the specific target pathogens.54-55 Therefore, a
simple, effective and integrated method for mLAMP detection is in great need.
With various advantages such as miniaturization, portability, automation, and integration,
microfluidic lab-on-a-chip has recently provided a platform for a variety of biomedical
applications including human health diagnostics (see Section 1.2.1).61, 65-74 Recently, microfluidic
chips integrated with LAMP have been developed for rapid pathogen detection such as
Staphylococcus aureus, Escherichia coli, and Mycobacterium tuberculosis.125-129 We also
developed a versatile PDMS/paper hybrid microfluidic biochip integrated with LAMP for rapid
and sensitive infectious disease diagnosis, as demonstrated in Chapter 3 and Chapter 4, but only
singleplexed detection of N. meningitidis or B. pertussis was demonstrated. With the benefits of
multiple compartments in microfluidic devices, multiplexed pathogen detection was reported by
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performing parallel singleplexed LAMP reactions in different independent compartments of a
microfluidic chip.125, 141-142 We also developed another paper/PDMS hybrid microfluidic biochip
for instrument-free multiplexed pathogen detection, as demonstrated in Chapter 4. However,
multiple-compartment-based multiplexed pathogen detection (different from mLAMP) usually
can only identify the occurrence of amplifications based on the byproducts from the reactions.
Although this compartment-based singleplex LAMP can detect multiple pathogens
simultaneously, as mentioned earlier, the reagent consumption and cost will be doubled, tripled or
even more. The DNA conditions in different compartments might be different, thus potentially
lead to variations among LAMP reactions in different compartments. On the contrary, mLAMP
detection can directly amplify and identify multiple DNA targets from different pathogens in one
reaction under the same conditions, but it is still challenging to achieve. In addition, most published
multiplexed detections did not fully integrate both DNA amplification and DNA quantitation on a
single microfluidic device.125, 139
Graphene oxide (GO) is a 2D nanomaterial with excellent fluorescence quenching
property.214 This property makes GO promising in developing simple and sensitive nanosensors.
The Li group previously reported a paper/PDMS hybrid microfluidic system integrated with
aptamers-functionalized GO nanosensors for one-step multiplexed pathogen detection, where
paper facilitated the facile integration of nanosensors on the microfluidic chip.116 Desorption of
the fluorescence labeled aptamers from the GO surface through hybridization with the target
pathogens could recover the quenched fluorescence for a simple “turn-on” detection strategy.
Despite the high simplicity of this one-step detection strategy, DNA amplification was not
integrated for high-sensitivity detection.
Therefore, by taking advantages of both GO nanosensors and LAMP DNA amplification
on a microfluidic lab-on-a-chip, we developed a paper/PMMA hybrid CD-like microfluidic
SpinChip integrated with both LAMP amplification and ssDNA probe-functionalized GO
nanosensors on a single device for mLAMP detection (ms-mLAMP). Multiple DNA targets can
be isothermally amplified in a single microzone (i.e. mLAMP). Individual targets can be further
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identified by integrated different ssDNA probe-functionalized nanosensors afterward. Dual
checkpoints through specific LAMP primers and specific DNA capture probes ensure extremely
high specificity of the method. More significantly, quantitation of multiple DNA targets was
achieved on the SpinChip. To facilitate seamless integration of the LAMP unit and the nanosensing
unit, we designed the microfluidic device in a novel CD-like SpinChip format where LAMP
amplicons from a single microzone can be readily transferred to multiple different nanosensing
microwells through the spinning of the bottom plate manually, without the use of any complicated
pneumatic values.
Therefore, the integrated LAMP and probe nanosensors provided a new simple solution
for mLAMP detection. In this work, we demonstrated the proof-of-concept of ms-mLAMP by
simultaneous detection of N. meningitidis and S. pneumoniae, two leading pathogens causing
bacterial meningitis. Bacterial meningitis is a global infectious disease with high fatality (30-60%
in developing nations) and morbidity, and becomes fatal within 24 hours if untreated (see Section
1.1.1).215 Thus, rapid and early detection of the exact type of meningitis is vital to the timely
prevention and treatment of the disease. The direct mLAMP detection for meningitis-causing
pathogenic microorganisms was achieved without time-consuming sample preparation procedures
or the requirement of centrifuges for DNA extraction and purification. The LODs for N.
meningitidis and S. pneumoniae of as low as 6 copies and 12 copies per assay were achieved in
about 1 hour. No washing or amplicon purification steps are needed in the assay procedures. To
the best of our knowledge, for the first time, our study provides a simple and effective microfluidic
approach for quantitative mLAMP detection.
6.2

Experimental section

6.2.1 Chemicals and materials
Table 6.1 and Table 6.2 list the sequence information of the LAMP primers and ssDNA
probes for N. meningitidis46, 216 and S. pneumoniae,47, 217 as well as the negative control probe
(NC1)218. All of the ssDNA probes were labeled with Cy3 at the 5’ end.
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Table 6.1: LAMP primer sequences for N. meningitidis and S. pneumoniae, respectively
Primer
FIP
BIP
F3
B3
FL
BL
Primer
FIP
BIP
F3
B3
BL

N. meningitidis LAMP primer sequences for the ctrA gene
Sequences (5’-3’)
CAAACACACCACGCGCATCAGATCTGAAGCCATTGGCCGTA
TGTTCCGCTATACGCCATTGGTACTGCCATAACCTTGAGCAA
AGC(C/T)AGAGGCTTATCGCTT
ATACCGTTGGAATCTCTGCC
CGATCTTGCAAACCGCCC
GCAGAACGTCAGGATAAATGGA
S. pneumoniae LAMP primer sequences for the lytA gene
Sequences (5’-3’)
CCGCCAGTGATAATCCGCTTCACACTCAACTGGGAATCCGC
TCTCGCACATTGTTGGGAACGGCCAGGCACCATTATCAACAGG
GCGTGCAACCATATAGGCAA
AGCATTCCAACCGCC
TGCATCATGCAGGTAGGA

No. of bases
41
42
19
20
18
22
No. of bases
41
43
20
15
18

Table 6.2: ssDNA probes
ssDNA probe
N. meningitidis
S. pneumoniae
NC1 (Influenza A)

Sequences (5’-3’)
Cy3-AACCTTGAGCAATCCATTTATCCTGACGTTCT
Cy3-GCGGATTCCCAGTTGAGTGTGCGTGTAC
Cy3-TGCAGTCCTCGCTCACTGGGCACG

No. of bases
32
28
24

All other chemicals and materials are listed in Section 2.1.
6.2.2 Bacterial culture and DNA preparation
The bacterial culture and DNA preparation protocols for N. meningitidis and S.
pneumoniae are described in Section 2.2. The calculation of determining the copy numbers of the
N. meningitidis and S. pneumoniae template DNA is demonstrated in Section 2.5.
6.2.3 Microfluidic SpinChip design and fabrication
As shown in Figure 6.1, the microfluidic SpinChip has two plates tightened with a screw
in a center. The bottom plate (Figure 6.1a right) contains a LAMP zone (diameter 4.0 mm, depth
1.5 mm), while the top plate (Figure 6.1a left) contains 12 detection wells (diameter 2.0 mm, depth
0.5 mm). A chromatography paper disk (diameter 2.0 mm) was tightly placed inside each detection
well serving as a 3D storage substrate for the Cy3-labeled ssDNA probe-functionalized
nanosensors. The detection wells are divided into 4 areas, which are designated for N. meningitidis
and S. pneumoniae detection (N.M. and S.P.) with their corresponding ssDNA probes, as well as
2 negative controls (NC1 and NC2). A non-target probe, Influenza A probe, is pre-loaded in NC1
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detection wells; No probes are pre-loaded in NC2 detection wells. In addition, there is an inlet
(diameter 1.5 mm) in the top plate, through which samples and reaction reagents are introduced
into the LAMP zone.
Fabrication of the microfluidic SpinChip was described in Section 2.3.2.

Figure 6.1: Schematic of the paper/PMMA hybrid microfluidic SpinChip for mLAMP detection.
(a) SpinChip layout. (b) Detection principle based on the interaction among the GO,
ssDNA probes and target LAMP products. (c) A photograph of the SpinChip.
6.2.4 On-chip LAMP and assay procedures
An 18 μL LAMP reaction mixture was prepared in a biosafety cabinet and introduced to
the LAMP zone from the inlet of the microfluidic SpinChip (Figure 6.2-1, SpinChip open),
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followed by rotating the top plate to cover the LAMP zone, and screwing the two plates tightly
(Figure 6.2-2, SpinChip closed). Once the SpinChip was closed, by using the heating film that
controlled by an inexpensive proportional−integral−derivative (PID)-based temperature controller
which was devised by our laboratory (see Section 3.2.4), the SpinChip was heated at 63 ℃ for 45
minutes for mLAMP reactions, followed by heated at 95 °C for 2 minutes to terminate mLAMP
reactions and to denature the LAMP products (a mixture of stem-loop DNA). After the mLAMP
reaction, the SpinChip was turned over and the bottom plate was rotated slowly. LAMP products
were distributed to different nanosensor detection wells separately to hybridize with their
corresponding Cy3-labeled ssDNA probes when the LAMP zone in the bottom plate passed by
different detection wells in the top plate (Figure 6.2-3, SpinChip spinning). After incubation for
20 minutes at room temperature, the SpinChip was scanned by a Nikon Fluorescence Microscope
(Melville, NY) to measure the fluorescence intensity, using the appropriate Cy3 optical filter, as
described in Section 2.4.2.
6.2.5 Direct detection of multiple pathogenic microorganisms
The ACSF buffer preparation process is demonstrated in Section 3.2.6.
Microorganisms were spiked in ACSF solutions to make artificial ‘clinical’ ACSF samples.
A tiny amount of bacterial colonies from each microorganism of N. meningitidis and S.
pneumoniae was swabbed and suspended in 1 mL ACSF buffer by adjusting the turbidity to
McFarland Standard 0.5 (Key Scientific Products, Stamford, TX), forming an ACSF sample
with an approximate bacterial density of 1.5 × 108 cfu/mL.180 To direct detect the pathogenic
microorganisms, 3 μL of the ACSF sample was mixed with 3 μL bacterial lysis buffer (that
contained 50 mM Tris buffer (pH 7.5), 4 M urea and 0.1% triton) to lyse the cells of the pathogenic
microorganisms and release their DNA. After incubating at room temperature for about 10
minutes, 1.5 µL of the lysate was directly used to prepare the LAMP mixture for the subsequent
on-chip mLAMP reaction and detection.
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6.2.6 Gel electrophoresis and fragment analysis
Gel electrophoresis was used to investigate and compare the gel electrophoresis-based
approach with our approach for mLAMP detection. The parameters are described in Section 2.6.
Applied Biosystems 3130xl Genetic Analyzer (Waltham, Mass.) was used to perform
fragment analysis of LAMP products to verify the success of the mLAMP reaction and detection.
6.3

Results and discussion

6.3.1 Principle of the paper/PMMA hybrid microfluidic SpinChip for mLAMP
Different substrates have their own advantages and limitations, as discussed in Section
1.2.3. For instance, PMMA is cost-effective, easy of fabrication, optically transparent, compatible
with a variety of chemical and biological reagents, and has moderately high mechanical stresses.
These properties make PMMA an attractive substrate for fabrication of various microfluidic
devices with a variety of applications.106-107 However, PMMA is often associated with additional
complicated chemical surface modifications for biosensor immobilization.115 Paper is low-cost,
has a 3D microstructures and a high surface-to-volume ratio property, large effective surface areas,
and can transport fluids via the capillary effect without the need of external pneumatic pumps.
Therefore, paper has become one of the most prevalent substrates for low-cost bioassays.93, 95
However, the paper substrate lacks the high performance in flow control demonstrated by polymer
substrates, and cannot effectively provide a closed system to prevent the reagent evaporation such
as in nucleic acid amplification process. In this work, the paper/PMMA hybrid SpinChip takes
advantages from both the substrates and avoid their limitations. For instance, along with ease of
liquid handling from PMMA, the introduction of porous paper inside the detection wells provides
a simple 3D substrate for the integration of ssDNA probe-functionalized GO nanosensors on the
chip, without using any complicated surface treatment and modifications. With the property of a
large surface-to-volume ratio, the porous paper substrate could improve reaction kinetics for rapid
assays.181
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As discussed in Section 6.1, one of the bottleneck challenges for mLAMP is how to
efficiently identify and quantify the detection targets from a number of complicated ladder-pattern
bands. Figure 6.4 shows one of such examples. The hybrid integrated microfluidic SpinChip
provide an unprecedented solution to address such an issue for mLAMP. After mLAMP reactions
in a single microzone in the SpinChip, a series of detection microwells integrated with different
DNA capture probe-functionalized nanosensors were designed to capture specific DNA targets,
thus allowing ease of target identification and quantitation.
The microfluidic SpinChip was designed in an innovative CD-like rotary format to
facilitate the integration of both mLAMP reactions and nanosensor detection. The two PMMA
plates were not permanently bonded. Instead, they were tightened by a screw in the center (see
Figure 6.1), which allowed the rotation of one plate over the other by loosening the screw slightly
during the spinning stage. As illustrated in Figure 6.2-1, during the reagent introduction stage, the
top plate is rotated to align the inlet in the top plate with the LAMP zone in the bottom plate
(SpinChip open), thus allowing us to add reagents from the inlet in the top plate to the LAMP zone.
After the reagent introduction, the top plate is spun manually (see Figure 6.2-2) and then tightened
such that the bottom LAMP zone is sealed to avoid reagent evaporation during the mLAMP
reaction stage at 63 °C for 45 minutes. When mLAMP reactions are completed, the SpinChip is
turned over and the original bottom plate is rotated manually over the original top plate, as shown
in Figure 6.2-3. When the LAMP zone passes by different detection wells underneath, the mLAMP
products will be in contact with the paper disks in different detection wells. The wicking effect of
paper and the gravity of the mLAMP solution assists easy and even distribution of mLAMP
products to all detection wells, without using any pneumatic valves or pumps. Although only 12
detection wells are designed in the current SpinChip, these microwells can be scaled up, and the
SpinChip provides a simple strategy to distribute reagents to numerous microwells evenly. This
feature is especially very useful for applications such as multiplexed detection and high-throughput
analysis in low-resource settings.
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When mLAMP products are distributed to the detection wells, amplified target DNA will
hybridize with specific capture probes immobilized in the paper disk in the detection wells. The
quenched fluorescence of the Cy3-labeled ssDNA capture probes will be recovered (see Figure
1b).116, 214 In the absence of the target mLAMP products, no obvious fluorescence restoration is
detected. Therefore, different targets can be readily identified and quantified from different
detection wells. The Li group used similar detection principles for the multiplexed detection of
food-borne pathogens using aptasensors in a paper/PDMS hybrid microfluidic device,116 and for
the high-sensitivity detection of environmental pollutants in a droplet microfluidic system.65
Except for one-time reagent addition at the beginning of the assay on the SpinChip, no any further
reagent addition and washing steps are required during the whole assay. This significant feature
transforms the complicated mLAMP into a very simple one-step assay with good throughput (e.g.
multiplexed detection and multiple-sample detection).

Figure 6.2: Working principle of the SpinChip for mLAMP which consists of (1) reagent
delivery, (2) mLAMP reaction, and (3) mLAMP detection.
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6.3.2 Optimization of ssDNA capture probe concentrations
The concentrations of the ssDNA probes can affect both the fluorescence quenching and
fluorescence recovery results, resulting in impacts on the detection sensitivity. Therefore, we first
optimized concentrations of the ssDNA probes by testing different concentrations (0.25 μM, 0.50
μM, 0.75 μM, and 1.0 μM) of the ssDNA probe targeting the N. meningitidis LAMP products (800
ng/μL). Figure 6.3 shows the fluorescence images of the SpinChip before fluorescence quenching
(Figure 6.3a, left), after quenching (Figure 6.3a, middle) and after recovery (Figure 6.3a, right),
and their corresponding fluorescence intensities (Figure 6.3b) at different ssDNA probe
concentrations. Three important factors, the fluorescence intensity after recovery, the recovery rate
(i.e. the percentages of the fluorescence intensities after recovery to the fluorescence intensities
before quenching) and the net fluorescence recovery (i.e. the fluorescence difference between after
recovery and after quenching) need to be considered because all of them can directly affect the
detection sensitivity. It can be seen that the fluorescence of the ssDNA probe was significantly
quenched; low fluorescence intensities below 800 arbitrary unit (a.u.) were observed for all
concentrations of the ssDNA probe. The fluorescence intensities after recovery, the recovery rate,
and the net fluorescence recovery increased with the increase of the ssDNA concentration.
Compared with the lower concentration of 0.25 µM, the fluorescence intensities after recovery,
the recovery rate, and the net fluorescence recovery of 1.0 µM of the capture probe increased from
2620 a.u. to 8450 a.u., 81% to 94%, and 3 folds to 10 folds, respectively. Therefore, given the
higher fluorescence intensity after recovery (8450 a.u.), greater recovery rate (94%) and higher net
fluorescence recovery (10 folds increase) observed from the ssDNA probe concentration of 1.0
μM, 1.0 μM ssDNA probe was chosen for the subsequent assays.
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Figure 6.3: Optimization of the ssDNA probe concentration. Fluorescence images (a) and the
corresponding fluorescence intensities (b) of different concentrations of the ssDNA
probe for N. meningitidis LAMP products (800 ng/μL) before quenching, after
quenching, and after fluorescence recovery.
6.3.3 ms-mLAMP detection of pathogenic microorganisms
Before testing on-chip mLAMP, we performed conventional tube-based LAMP reactions
by adding extracted DNA samples of N. meningitidis and S. pneumoniae individually (singleplex
LAMP) and both (mLAMP), and investigated the feasibility of the conventional gel
electrophoresis-based mLAMP method. As shown in Figure 6.4, although ladder-pattern bands
from mLAMP products of both N. meningitidis and S. pneumoniae could be observed, there were
no noticeable differences when compared with the ladder-pattern bands from singleplex LAMP
products of N. meningitidis and S. pneumoniae, respectively. Based on the ladder-pattern bands,
we cannot conclude if the mLAMP products contained only the LAMP products of N. meningitidis,
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S. pneumoniae, or both. This problem mainly came from the complex mixture of stem-loop
different-sized LAMP products from each DNA template DNA, making it almost impossible to
distinguish one target from mLAMP! In contrast, each PCR template only generates one singlesized product, which makes PCR advantageous in multiplexed detection.219
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Figure 6.4: Gel electrophoresis analysis of the products from singleplex LAMP and mLAMP.
Lanes 1, 100 bp marker; Lanes 2 and 3, singleplex LAMP products of N.
meningitidis and S. pneumoniae respectively; Lane 4, mLAMP products of both N.
meningitidis and S. pneumoniae.
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To address the aforementioned issue, we conducted mLAMP reactions on the SpinChip
and investigated the performance our approach for mLAMP detection. ACSF samples with spiked
pathogenic microorganisms of both N. meningitidis and S. pneumoniae was used to mimic real
clinic samples. Pathogenic microorganisms were lysed by using the simple centrifuge-free lysis
procedure that we developed,177 which avoided complicated sample preparation procedures.
Results shown in Figure 6.5 demonstrated the successful mLAMP detection of multiple pathogenic
microorganisms in ACSF samples. The recovered fluorescence intensities from N. meningitidis
and S. pneumoniae were about 4 folds higher than those from the negative controls. Compared
with the conventional gel electrophoresis, our ms-mLAMP provided a much simpler and more
effective method for mLAMP detection. In addition, these separated and highly-specific
nanosensor detection wells laid a good foundation for quantitative mLAMP detection.
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Figure 6.5: ms-mLAMP detection of meningitis pathogenic microorganisms, N. meningitidis and
S. pneumoniae. Fluorescence images (a) and the corresponding fluorescence
intensities (b) of nanosensor detection wells after quenching and after fluorescence
recovery.
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We further confirmed the success of our SpinChip for mLAMP detection by using fragment
analysis. The LAMP primers (BIPs) for N. meningitidis and S. pneumoniae were modified with
FAM and Cy3, respectively. Singleplex LAMP and mLAMP reactions were conducted on the
SpinChip by using ACSF samples of individual N. meningitidis, S. pneumoniae, and both. Then
the products from the on-chip singleplex LAMP and mLAMP reactions were collected, purified,
and analyzed by fragment analysis. Results were shown in Figure 6.6. Blue peaks (150, 173, 238
and 253 bp) and green peaks (178, 258 and 267 bp) were major LAMP products from singleplex
LAMP amplification of N. meningitidis and S. pneumoniae, respectively. Some peaks (e.g. 173
and 178 bp) in the mLAMP products from the mixture of N. meningitidis and S. pneumoniae were
too close to be resolved by the conventional gel electrophoresis method. It might be challenging
to completely separate all the peaks from one-color capillary electrophoresis or fragment analysis.
But thanks to the multiple-color high-resolution fragment analysis, all these specific peaks were
well resolved and identified, which further confirmed the success of our microfluidic SpinChip
method for mLAMP reactions and detection.
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Figure 6.6: Fragment analysis of the products from singleplex LAMP and mLAMP.
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6.3.4 Calibration curves & LODs
Our ms-mLAMP is capable of achieving not only identification of targets (i.e. qualitative
analysis) but also quantitative mLAMP detection due to the integrated nanosensors, a significant
feature of our ms-mLAMP, because most reported on-chip LAMP and mLAMP method did not
achieve quantitative analysis.51-53, 125, 139 mLAMP reactions amplify multiple DNA targets lays a
solid foundation for high-sensitivity detection;42 while quantitative mLAMP can quantify the
pathogen concentrations to estimate the infection seriousness. By testing a serial of 10-fold diluted
initial template DNA samples, we investigated the detection sensitivity and LODs of our approach
for simultaneous detection of N. meningitidis and S. pneumoniae. The recovered fluorescence
intensities corresponding to various copy numbers of initial template DNA were recorded from
different nanosensor detection wells to generate calibration curves, as shown in Figure 6.7. It can
be seen that there was a linear relationship between the recovered fluorescence intensities and the
logarithm of initial copy numbers of the template DNA in the range of 6-6×105 copies and 121.2×106 copies per assay for N. meningitidis and S. pneumoniae, respectively. The greater slope
from the curve of N. meningitidis than that of S. pneumoniae indicated a higher sensitivity of the
nanosensors. On the basis of the 3-fold standard deviations of the mean fluorescent intensities of
the negative control, the LODs for N. meningitidis and S. pneumoniae were found to be as low as
6 copies and 12 copies per assay, respectively, which were comparable to real-time PCR.37, 220
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Figure 6.7: Calibration curves of the fluorescence intensity after recovery versus the initial copy
number of template DNA of N. meningitidis and S. pneumoniae, with R2 of 0.98
and 0.97, respectively.
In this work, other than quantitative analysis of the initial target concentrations (i.e. initial
copy numbers of DNA templates), we also demonstrated the capability of the probe-functionalized
nanosensors for quantification of mLAMP amplicons by using a series of diluted N. meningitidis
and S. pneumoniae LAMP products (see Figure 6.8). The GO nanosensors were able to detect
LAMP products of N. meningitidis and S. pneumoniae at concentrations of as low as 80 ng/μL and
87.5 ng/μL, respectively.
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Figure 6.8: Calibration curves of the fluorescence intensity after recovery versus the target
LAMP products concentration of N. meningitidis and S. pneumoniae, with R2 for N.
meningitidis and S. pneumoniae of 0.99 and 0.97, respectively.
6.3.5 Specificity test
The specificity of our ms-mLAMP was explored by testing N. meningitidis and S.
pneumoniae DNA samples with their corresponding and non-corresponding ssDNA probes.
Specific ssDNA probes for N. meningitidis, S. pneumoniae, and NC1 at an optimized concentration
(1.0 μM) were preloaded in the detection wells. Then we introduced N. meningitidis and S.
pneumoniae DNA samples separately for the mLAMP reaction and the subsequent detection on
two different SpinChips. As shown in Figure 6.9 and Figure 6.10, only the target DNA sample
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with its corresponding ssDNA probes generated bright fluorescence. As shown in Figure 6.9b and
Figure 6.10b, the net recovered fluorescence intensities of N. meningitidis and S. pneumoniae
samples with their corresponding probes were about 8.1 folds and 6.6 folds higher than those
microwells with their non-corresponding probes, respectively. The results indicated the high
specificity of our approach without cross reactions or interferences.
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Figure 6.9: Specificity investigation by testing N. meningitidis sample with its corresponding and
non-corresponding ssDNA probes. (a) Fluorescence images of nanosensor
microwells after quenching (left) and after recovery (right). (b) Fluorescence
intensities of nanosensor microwells after quenching, after recovery, and net
recovery.
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Figure 6.10: Specificity investigation by testing S. pneumoniae samples with its corresponding
and non-corresponding ssDNA probes. (a) Fluorescence images of nanosensor
microwells after quenching (left) and after recovery (right). (b) Fluorescence
intensities of nanosensor microwells after quenching, after recovery, and net
recovery.
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6.3.6 Shelf life test
The shelf life of the ready-to-use hybrid microfluidic SpinChips was also studied. A series
of ready-to-use SpinChips were placed in a dark environment at room temperature. The
fluorescence intensities of those different SpinChips were measured after different time periods.
The highest fluorescence intensity on Day 0 was used to normalize the rest fluorescence intensities
to reflect their performance over a time period of 73 days. As can be seen from Figure 6.11, the
performance of the SpinChip decreased by ~20% during the first two weeks. After that, it
maintained a stable performance, by the end of the experimental period. The performance
remained higher than 70% during the whole experimental period. It is expected those SpinChips
could maintain close to 100% performance if they were stored in refrigerators during that time
period. The stable performance of the SpinChip over a long period of time could be attributed to
two reasons. First, GO can protect ssDNA probes against enzymatic cleavage.221 Second, highly
interwoven paper fibers provide a 3D matrix for preservation of ssDNA probes from harsh
environmental elements and prevent ssDNA loss in the form of aerosols in air.177
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Figure 6.11: Study of the shelf life of the ready-to-use hybrid microfluidic SpinChips over a time
period of 73 days. The highest fluorescence intensity on Day 0 was used to
normalize the rest fluorescence intensities to reflect their performances at different
time points.
6.4

Summary
We developed a PMMA/paper hybrid CD-like microfluidic SpinChip integrated with

ssDNA probe-functionalized nanosensors for mLAMP detection (ms-mLAMP). The integrated
mLAMP reactions and nanosensors on the chip provided a simple but superior solution to address
difficulties of conventional mLAMP in the identification and quantitative of multiple targets. The
innovative CD-like rotary design of the SpinChip allowed a simple and seamless connection
between the mLAMP unit and the nanosensor detection unit, without relying on any peripheral
pumps and pneumatic values. During the whole assay, after the first addition of reagents, no other
reagent addition or washing steps were needed, which enabled a “one-step sample-to-answer”
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strategy for mLAMP reactions and detection. Using the ms-mLAMP, two types of pathogenic
microorganisms, N. meningitidis and S. pneumoniae, were successfully amplified and quantified
on-chip with high sensitivity and specificity, demonstrating the proof of concept. The LODs for
N. meningitidis and S. pneumoniae of 6 copies and 12 copies per assay were achieved, respectively,
indicating high detection sensitivity. Given these significant features, the ms-mLAMP provide an
unprecedented opportunity for broad applications of mLAMP.
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Chapter 7: Conclusions and Perspectives



This chapter states the concluding remarks and future directions of the research work in
this dissertation.
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7.1

Concluding remarks
Three paper/polymer hybrid microfluidic biochips have been developed for pathogen

detection, aiming to provide low-cost POC testing platforms for infectious disease diagnosis. In
this dissertation, rapid diagnosis of meningitis and pertussis, multiplexed pathogen detection, and
quantitative mLAMP detection has been successfully demonstrated using those hybrid
microfluidic biochips. In conclusion:
1. These paper/polymer hybrid microfluidic biochips are low-cost.
2. Different substrates have different advantages and limitations. These hybrid biochips
can draw more benefits from both the polymer and paper substrates and avoid their limitations.
3. Rapid and sensitive detection of N. meningitidis on a paper/PDMS hybrid microfluidic
biochip was easily achieved by the naked eye without using any specialized instruments. The
hybrid biochip enabled a stable diagnostic performance for a long period of time. By using a
centrifuge-free lysis process, pathogenic microorganisms could be directly detected without any
laborious sample preparation process such as DNA extraction.
4. The broader application of our microfluidic approach was further demonstrated by
testing the whooping cough-causing bacterium, B. pertussis. The testing results for 100 human
clinical samples exhibited high specificity and sensitivity, which was comparable to costly qPCR.
5. On the basis of singleplexed pathogen detection, instrument-free multiplexed pathogen
detection on another paper/PDMS hybrid microfluidic biochip was achieved. Simultaneous
detection of three most common meningitis-causing pathogens, N. meningitidis, S. pneumoniae
and Hib was successful demonstrated.
6. The quantitative mLAMP detection for infectious diseases on a paper/PMMA hybrid
CD-like microfluidic SpinChip was achieved. Paper in this hybrid system facilitated the simple
integration of nanosensors on the SpinChip. This hybrid SpinChip provided a simple and effective
microfluidic approach for quantitative mLAMP detection.
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7. The hybrid microfluidic biochips demonstrate great potential applications for infectious
disease diagnosis in low-resource settings where financial and medical resources are extremely
limited.
7.2

Future directions

7.2.1 A fully integrated and battery-powered Bioanalyzer
A portable, fully integrated and battery-powered Bioanalyzer can help achieve a rapid,
sensitive and instrument-free infectious disease diagnosis on hybrid microfluidic biochips with
simple operations. This Bioanalyzer should have the following characteristics:
(1) Fully integrated. Several functional units including a heating unit, a microfluidic
biochip, a detection unit, and a data analysis unit should be integrated into this Bioanalyzer. As
demonstrated in the dissertation, the heating unit could be a heating film controlled by an
inexpensive PID-based temperature controller, and the microfluidic biochips should be allowed to
be easily placed on the heating film for on-chip LAMP reactions. Light emitting diodes (LEDs)
and a cell phone camera (or other inexpensive detectors) compose the detection unit. The LEDs
with different wavelengths are above the microfluidic biochip and should be capable of being
switched to satisfy the need of excitation for different fluorescence dyes such as calcein and Cy3.
A cell phone camera or a low-cost charge-coupled device (CCD) camera is used to take a
photograph under the LED light at a certain wavelength. Then the camera captured image can be
sent to a server via the internet, or processed by a smartphone-based application for further data
analysis on the basis of gray values, showing a yes/no qualitative result or even indicating the
infection seriousness.
(2) Fully battery-powered. The Bioanalyzer that includes the heating unit with a heating
film and the detection unit with LEDs should be fully battery-powered. This will be significant for
POC diagnosis of infectious diseases in poor areas where AC electricity supply may not be stable
or available.

133

(3) Portable. The Bioanalyzer should be miniaturized, light, compact, and easy to be carried
for various settings such as physician’s offices, school health centers, and other resource-limited
settings.
(4) Compatible. The Bioanalyzer should be compatible with various formats of
microfluidic biochips to obtain broad applications for different infectious disease diagnosis.
7.2.2 Future direction for meningitis diagnosis
Clinical CSF samples should be tested and compared with the qPCR test in the future to
validate the diagnostic performance of the paper/polymer hybrid microfluidic biochips for
bacterial meningitis diagnosis.
7.2.3 Future direction for pertussis diagnosis
Instead of conducting the tests in a laboratory setting, field validation and testing for
pertussis diagnosis at a physician’s offices, a school health center or other resource-limited settings
is needed in the future. In this way, it can be validated that the paper/polymer hybrid microfluidic
biochip is capable of being used as POC diagnostic platforms for pertussis diagnosis. In addition,
multiplexed detection of Bordetella species including B. pertussis, B. holmesii, and B.
parapertussis should be performed since they can be easily mistaken for each other.
7.2.4 Future direction for mLAMP
In the dissertation, two pathogens (N. meningitidis and S. pneumoniae) were tested to
investigate the feasibility and performance of mLAMP detection on a hybrid microfluidic
SpinChip. Given that larger number of primers for multiplex target sets would increase the
complexity of the LAMP reaction system, three or more target pathogens should be tested to
evaluate the capability of the hybrid SpinChip for mLAMP reaction and detection by optimizing
the LAMP primer design for multiplex target sets. In addition, by using the Bioanalyzer described
in Section 7.2.1, fluorescence signals could be simply detected by a cellphone camera under a LED
light without relying on a fluorescence microscope.
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7.2.5 Future direction of hybrid microfluidic biochips
This dissertation demonstrates the application of several paper/polymer hybrid
microfluidic biochips integrated with LAMP for infection disease diagnosis. By designing and
changing corresponding LAMP primers, other pathogens that cause infectious diseases, such as
Zika, foodborne pathogens, and Mycobacterium tuberculosis could be tested on the paper/polymer
hybrid microfluidic biochips.
In addition, with unique advantages, the hybrid microfluidic biochips should have a variety
of applications, such as 3D cell culture, drug discovery and drug test, chemical synthesis, one-step
detection of aqueous insoluble molecules, and so on.
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